MURAKI Masato

    Kindai University Nara Hospital Professor/General Manager
Last Updated :2024/03/24

Researcher Information

Degree

  • (BLANK)(Kinki University)

URL

J-Global ID

Research Interests

  • 臨床免疫学   アレルギー学   呼吸器病学   Infection   Respiration   Lung   Allergy   

Research Areas

  • Life sciences / Allergies and connective tissue disease
  • Life sciences / Respiratory medicine
  • Life sciences / Internal medicine - General

Academic & Professional Experience

  • 1998 - 1999  メイヨクリニック、免疫学、 Research fellow
  • 1998 - 1999  Mayo Clinic, Department of Immunology, Research fellow

Education

  •        - 1993  Kindai University  Graduate School of Medical Sciences
  •        - 1993  Kinki University  Graduate School, Division of Medicine
  •        - 1987  Kindai University  Faculty of Medicine  Department of Medicine
  •        - 1987  Kinki University  Faculty of Medicine

Association Memberships

  • 世界気管支学会   国際喘息学会   日本呼吸器内視鏡学会   日本感染症学会   日本呼吸器学会   日本アレルギー学会   日本内科学会   

Published Papers

  • 近畿大学における新型コロナワクチン職域接種
    藤本 美香; 寺本 恭子; 山本 みどり; 池崎 友紀; 木田 美千代; 山岡 琴美; 村上 華子; 秋田 繁則; 小池 優香; 明和 美桂; 明石 尚夫; 杉本 照信; 岩森 秀樹; 甲斐 冴; 肥田 仁一; 杉本 圭相; 村木 正人; 宮澤 正顯; 東田 有智
    全国大学保健管理研究集会プログラム・抄録集 (公社)全国大学保健管理協会 61回 56 - 56 2023/10
  • Soichiro Hanada; Masato Muraki; Yoshiyuki Kawabata; Kazuya Yoshikawa; Toshiyuki Yamagata; Tadao Nagasaki; Yushiro Ohara; Naoki Oiso; Hisako Matsumoto; Yuji Tohda
    Patient preference and adherence 17 2847 - 2853 2023 
    PATIENTS AND METHODS: A questionnaire survey was administered to 18, 14, and 3 patients introduced to home self-injection of dupilumab or mepolizumab using a pen-type device for atopic dermatitis, asthma alone, and asthma plus chronic rhinosinusitis with nasal polyps, respectively. RESULTS: All but one participant wished to continue self-injection. Most participants affirmed the reduction in copayment (88.6%) and saving time and labor for hospital visits (88.6%). Six patients who received dupilumab complained of side effects, but all, except for one, continued the treatment. Of the 13 patients who had previously used a syringe-type device, 10 preferred the pen type because of its ease of use, while 3 (23%) preferred the syringe type because of the self-adjustable injection speed for pain control. CONCLUSION: Administration of biologics using pen-type devices is easier, and the introduction of home self-injection leads to a reduction in outpatient visits and copayment.
  • 橋本 和彦; 木谷 光太郎; 寺口 皓; 吉川 知宏; 天野 智佳子; 田村 さやか; 澤口 博千代; 嶋田 高広; 木村 豊; 村木 正人
    日本外科感染症学会雑誌 (一社)日本外科感染症学会 18 (1) 265 - 265 1349-5755 2021/11
  • Masato Muraki; Yuki Kunita; Ken Shirahase; Ryo Yamazaki; Soichiro Hanada; Hirochiyo Sawaguchi; Yuji Tohda
    BMC pulmonary medicine 21 (1) 26 - 26 2021/01 [Refereed]
     
    BACKGROUND: In chronic obstructive pulmonary disease (COPD) patients, combination treatment with long-acting muscarinic antagonist (LAMA) and long-acting β2 agonist (LABA) increases forced expiratory volume in one second and reduces symptoms compared to monotherapy. In Japan, three different once-daily fixed-dose combinations (FDCs) have been prescribed since 2015, although a direct comparison of these FDCs has never been performed. The objective of the present study was to compare the effectiveness, preference, and safety of three LAMA/LABA FDCs-glycopyrronium/indacaterol (Gly/Ind), umeclidinium/vilanterol (Ume/Vil), and tiotropium/olodaterol (Tio/Olo)-in patients with COPD. METHODS: We enrolled 75 COPD outpatients (male:female ratio, 69:6; 77.4 ± 6.9 years). A prospective, randomized, crossover study was conducted on three groups using three FDCs: Gly/Ind; Ume/Vil; and Tio/Olo. Each medication was administered for 4 weeks before crossover (total 12 weeks). After each FDC administration, a respiratory function test and questionnaire survey were conducted. A comparative questionnaire survey of all three LAMA/LABA FDCs was conducted after 12 weeks (following administration of final FDC). RESULTS: No significant differences in COPD Assessment Test or modified Medical Research Council dyspnea questionnaire were reported in the surveys completed after each FDC administration; no significant differences in spirometric items were observed. In the final comparative questionnaire survey, patients reported better actual feeling of being able to inhale following Gly/Ind administration compared with Tio/Olo, although no significant differences in adverse events or other evaluations were reported. CONCLUSIONS: The three LAMA/LABA FDCs administered to COPD patients show similar effects and safety, although some minor individual preference was reported. Trial registration This study retrospectively registered with the University Hospital Medical Information Network Clinical Trials Registry (number UMIN000041342, registered on August 6, 2020).
  • Masato Muraki; Hirohito Kita; Gerald J Gleich
    Clinical and molecular allergy : CMA 18 (1) 24 - 24 2020/12 [Refereed]
     
    BACKGROUND: Eosinophils play an important role in allergic inflammation. Glucocorticosteroids have been used as an anti-inflammatory medication for inflammatory diseases involving eosinophil infiltration. Some effect of nebulized lidocaine has been reported when treating certain patients with asthma, which is also an inflammatory disease. The goal of this study was to examine the effects of dexamethasone and lidocaine on eosinophil proliferation and differentiation using a model of human umbilical cord blood mononuclear cells (UCMC) cultured with IL-5. METHODS: UCMC were cultured with IL-5 (5 ng/mL) for 4 weeks. The effects of dexamethasone and lidocaine on the number and morphology of eosinophilic cells were visualized with Wright-Giemsa and cyanide-resistant peroxidase stains. Moreover, the effect on eosinophil-derived neurotoxin (EDN) and eosinophil peroxidase (EPX) contents in cultured cells were evaluated using radioimmunoassay. RESULTS: The number of eosinophilic cells and EDN and EPX content in cultured cells increased in a time-dependent manner in the presence of IL-5. Dexamethasone treatment slightly decreased the number of eosinophilic cells in one week, but this effect was lost in 2-4 weeks. Macrophages in cultured UCMC treated with dexamethasone contained more eosinophil granule proteins. Both EDN and EPX content in cultured cells were reduced by dexamethasone. Lidocaine decreased the number of eosinophilic cells and reduced both EDN and EPX contents in cultured cells. CONCLUSIONS: Dexamethasone suppressed the production of eosinophil granule proteins and may also induce apoptosis of eosinophils, while lidocaine suppresses eosinophilopoiesis.
  • Masato Muraki; Kyuya Gose; Soichiro Hanada; Hirochiyo Sawaguchi; Yuji Tohda
    Drug delivery 24 (1) 1395 - 1400 2017/11 [Refereed]
     
    Two main types of devices are used to facilitate the administration of inhaled corticosteroid (ICS) and long-acting β-agonist (LABA) in combination, dry powder inhalers (DPIs) and pressurized metered-dose inhalers (pMDIs). There are few reports comparing the effects of the two devices, and it is unknown which should be recommended for asthma patients with given sets of characteristics. In the current study, the beneficial effects and side effects associated with DPIs and pMDIs were compared, and the question of which device should be recommended for asthma patients was investigated. A prospective, randomized, crossover, comparative study in adult outpatients with asthma was conducted using salmeterol/fluticasone propionate combination (SFC) 50 μg/250 μg, one inhalation of Adoair® 250 Diskus® twice daily or two inhalations of Adoair® 125 Aerosol twice daily, for 8 weeks. Questionnaires, exhaled nitric oxide (FeNO) tests and pulmonary function tests were administered after the use of each device for 8 weeks, and the results derived from each device were compared. Sixty-eight subjects were included in the final analysis. There were no significant differences between quality-of-life scores, FeNO, spirometry test results and forced oscillation results. With regard to patient preferences, 57.4% preferred the Adoair® Aerosol and 35.3% preferred the Adoair® Diskus®, as determined via the comparative evaluation questionnaire. Although DPI prescription accounts for the predominant market share of combined ICS/LABA in Japan, patients preferred a pMDI device to a DPI device. Compared to DPIs, pMDIs may be the preferential choice for patients with asthma.
  • 西川 侑輝; 御勢 久也; 和田 翔大; 澤口 博千代; 村木 正人; 若狭 朋子; 太田 善夫; 寺嶋 応顕; 上田 眞也; 明石 雄策; 塩野 裕之; 東田 有智
    気管支学 (NPO)日本呼吸器内視鏡学会 38 (5) 449 - 449 0287-2137 2016/09
  • Soichiro Hanada; Hirochiyo Sawaguchi; Shota Wada; Takeshi Ohno; Masato Muraki
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 104 (5) 979 - 83 0021-5384 2015/05
  • Soichiro Hanada; Shota Wada; Takeshi Ohno; Hirochiyo Sawaguchi; Masato Muraki; Yuji Tohda
    International journal of chronic obstructive pulmonary disease DOVE MEDICAL PRESS LTD 10 69 - 77 1178-2005 2015 [Refereed]
     
    Background: Tiotropium (Spiriva) is an inhaled muscarinic antagonist for patients with chronic obstructive pulmonary disease (COPD), and is available in two forms: the HandiHaler and the Respimat inhaler. The aim of this study was to investigate the handling of and preference for each device immediately after switching from the HandiHaler to the Respimat and 2-3 years after the switch. Materials and methods: The study comprised two surveys. A questionnaire was first administered to 57 patients with COPD (male: female 52: 5, mean age 73.6 +/- 7.1 years) 8 weeks after switching from the HandiHaler (18 mu g) to the Respimat (5 mu g). A second similar but simplified questionnaire was administered to 39 of these patients who continued to use the Respimat and were available for follow-up after more than 2 years. Pulmonary function was also measured during each period. Results: In the first survey, 17.5% of patients preferred the HandiHaler, and 45.6% preferred the Respimat. There were no significant changes in pulmonary function or in the incidence of adverse events after the switch. In the second survey, performed 2-3 years later, the self-assessed handling of the Respimat had significantly improved, and the number of patients who preferred the Respimat had increased to 79.5%. Conclusion: The efficacy of the Respimat was similar to that of the HandiHaler. This was clear immediately after the switch, even in elderly patients with COPD who were long-term users of the HandiHaler. The preference for the Respimat increased with continued use.
  • Masato Muraki; Shota Wada; Takeshi Ohno; Souichirou Hanada; Hirochiyo Sawaguchi; Takashi Iwanaga; Hiroaki Kume; Yuji Tohda
    Drug delivery INFORMA HEALTHCARE 21 (5) 321 - 7 1071-7544 2014/08 [Refereed]
     
    Background: The systemic administration of theophylline is useful for asthma treatment. However its narrow therapeutic range makes it difficult to use. Little is known about its potential in inhalation therapy, particularly repeated inhalation. Objective: The purpose of this study is to investigate the therapeutic usefulness of inhaled aminophylline in an asthma model. Methods: The effects of pretreatment with inhaled aminophylline (25 mg/mL for 30 min/dose) on airway response and inflammation after an ovalbumin (OVA) challenge and airway hypersensitivity to acetylcholine (Ach) were evaluated using guinea pigs sensitized with OVA. Results: Aminophylline relaxed the ACh-induced contraction of tracheal smooth muscle in vitro in a concentration-dependent manner. Pretreatment with single-dose aminophylline inhalation suppressed OVA-induced airway constriction to the same extent as the intraperitoneal pretreatment with high-dose aminophylline (10-20 mg/kg). However, pretreatment with single-dose aminophylline inhalation did not suppress eosinophil infiltration into airways (neither bronchoalveolar lavage [BAL] fluid nor lung tissue) and did not suppress airway hyperreactivity to ACh, 24 h after OVA challenge. Repeated inhalation of aminophylline (twice daily for 7 days) suppressed the infiltration of eosinophils and suppressed airway hypersensitivity to ACh. In addition, high concentrations of aminophylline inhibited production of oxygen radicals by BAL cells. Conclusion: Single-dose inhalation treatment with aminophylline has transient but relatively strong bronchodilating effects due to delivery of high doses into local airways. Repeated inhalation treatment suppressed airway inflammation and hypersensitivity induced by allergens. Therefore, inhaled aminophylline may be useful for asthma treatment.
  • 大野 剛史; 和田 翔大; 花田 宗一郎; 澤口 博千代; 村木 正人; 東田 有智; 岩崎 剛和
    アレルギー 一般社団法人 日本アレルギー学会 63 (3) 590 - 590 2014
  • Takeshi Ohno; Shota Wada; Souichirou Hanada; Hirochiyo Sawaguchi; Masato Muraki; Yuji Tohda
    International journal of chronic obstructive pulmonary disease DOVE MEDICAL PRESS LTD 9 107 - 14 1176-9106 2014 [Refereed]
     
    Background: Indacaterol is a novel, once-daily, inhaled, long-acting beta 2-agonist for patients with chronic obstructive pulmonary disease (COPD). The study objective was to evaluate the efficacy of indacaterol on quality of life and pulmonary function in patients with COPD in a real-world setting, and also to evaluate its inhaler device (Breezhaler (R)), which is important for both adherence and management. Methods: Twenty-eight outpatients with COPD were treated with indacaterol (150 mu g once daily for 8 weeks), and the effects on pulmonary function were evaluated using a questionnaire survey with the modified Medical Research Council (mMRC) dyspnea scale and COPD assessment test (CAT) before and after treatment. Similar investigations were also performed separately among different baseline medications. Moreover, original questionnaire surveys for indacaterol and its device were performed. Results: Overall, mMRC dyspnea scale and CAT scores significantly improved (1.96 +/- 1.04 to 1.57 +/- 1.07 and 17.39 +/- 8.23 to 12.82 +/- 8.42, respectively; P<0.05). Significant improvements in forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1) were also observed on pulmonary function tests (2.91 +/- 0.66 L to 3.07 +/- 0.65 L and 1.46 +/- 0.60 L to 1.58 +/- 0.59 L, respectively; P<0.05). Replacement therapy from salmeterol to indacaterol significantly improved mMRC and FVC values, but did not significantly improve CAT scores or other pulmonary functions. Add-on therapy with indacaterol significantly improved mMRC score, CAT score, FVC, and FEV1, regardless of whether tiotropium was used as a baseline treatment. All subjects in a questionnaire survey found the inhaler device easy to use. There were no serious adverse events leading to treatment discontinuation. Conclusion: Indacaterol is thought to be effective and well tolerated as a bronchodilator for the management of COPD. Treatment with indacaterol in addition to a long-acting muscarinic antagonist was also useful.
  • 久米裕昭; 西山理; 東本有司; 中島宏和; 村木正人; 東田有智
    アレルギー・免疫 20 (12) 1856 - 1864 1344-6932 2013/11
  • 花田 宗一郎; 大野 剛史; 田村 光信; 澤口 博千代; 村木 正人; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 62 (3) 402 - 402 2013
  • 大野 剛史; 花田 宗一郎; 田村 光信; 澤口 博千代; 村木 正人; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 61 (3) 486 - 486 2012
  • 山藤 啓史; 村木 正人; 大野 剛史; 花田 宗一郎; 忌部 周; 田村 光信; 澤口 博千代; 牧野 靖; 佐藤 隆司; 西山 理; 山縣 俊之; 佐野 博幸; 岩永 賢司; 東本 有司; 中島 宏和; 吉田 耕一郎; 久米 裕昭; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 61 (9) 1576 - 1576 2012
  • 花田 宗一郎; 大野 剛史; 田村 光信; 澤口 博千代; 村木 正人; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 61 (9) 1570 - 1570 2012
  • 村木 正人; 田村 光信; 澤口 博千代; 忌部 周; 山藤 啓史; 佐藤 隆司; 岩永 賢司; 久米 裕昭; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 60 (9) 1376 - 1376 2011
  • Yuji Higashimoto; Toshiyuki Yamagata; Noritsugu Honda; Ryuji Satoh; Hiroyuki Sano; Takashi Iwanaga; Takayuki Miyhara; Masato Muraki; Katsuyuki Tomita; Yuji Tohda; Kanji Fukuda
    Geriatrics & gerontology international WILEY-BLACKWELL PUBLISHING, INC 11 (1) 32 - 8 1444-1586 2011/01 [Refereed]
     
    Aim: Body mass index (BMI) is closely associated with mortality in chronic obstructive pulmonary disease (COPD). Systemic inflammation has been suggested as one of the mechanisms of malnutrition in COPD. This study investigated the relationships of clinical variables and inflammatory biomarkers with BMI in COPD in an aging population. Methods: Baseline levels of serum biomarkers were determined for 69 patients with stable male COPD. Multivariate logistic regression was used to evaluate associations between clinical variables, including emphysema scores, and biomarkers with BMI. Results: Twenty eight patients were categorized as low BMI (< 20 kg/m2). BMI was inversely correlated with serum alpha 1-antitrypsin (alpha 1-AT) concentration and emphysema scores, and was positively correlated with forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV(1)). Multivariate logistic regression analysis showed that alpha 1-AT was independently associated with BMI. Conclusion: Low BMI was associated with the severity of emphysema and systemic inflammation reflected by elevated alpha 1-AT level. Geriatr Gerontol Int 2011; 11: 32-38.
  • Yuji Higashimoto; Noritsugu Honda; Toshiyuki Yamagata; Toshiki Matsuoka; Kazushige Maeda; Rhyuji Satoh; Osamu Nishiyama; Hiroyuki Sano; Takashi Iwanaga; Takayuki Miyara; Masato Muraki; Katsuyuki Tomita; Hiroaki Kume; Ichiro Miyai; Yuji Tohda; Kanji Fukuda
    Respiration; international review of thoracic diseases 82 (6) 492 - 500 0025-7931 2011 [Refereed]
     
    BACKGROUND: Exertional dyspnea is the primary symptom that limits exercise in patients with chronic obstructive pulmonary disease (COPD). It is unknown which activated brain area is associated with this symptom in COPD patients. OBJECTIVES: To investigate the activation of cortical areas associated with dyspnea during exercise in COPD patients. METHODS: COPD patients (n = 10) and age-matched controls (n = 10) performed mild-intensity constant work rate cycle exercise (40% of their symptom-limited peak work rates) for 10 min, while cerebral hemodynamics and oxygenation were measured by near-infrared spectroscopy (NIRS). Ventilatory responses (breathing pattern and pulmonary gas exchange) and Borg scale ratings of dyspnea and leg fatigue were measured during exercise. Three NIRS probes were placed over the prefrontal and temporoparietal cortical regions of the subjects' heads. Changes in cortical oxyhemoglobin (oxy-Hb), deoxyhemoglobin (deoxy-Hb), and total hemoglobin (total Hb) concentrations from baseline recordings were measured. Increased oxy-Hb (oxygenation) was assumed to reflect cortical activation. RESULTS: Oxy-Hb concentration was significantly increased in the prefrontal region during exercise in both groups but not in the temporoparietal regions. The change in prefrontal oxy-Hb concentration of COPD patients was not different from that of controls. Dyspnea scores were positively correlated with changes in oxy-Hb concentrations of the prefrontal regions in both groups. Multivariate analysis showed that oxy-Hb concentration in the prefrontal region was the best predictor of dyspnea in both groups. CONCLUSIONS: Exertional dyspnea was related to activation (oxygenation) of the prefrontal cortex in COPD patients and control subjects.
  • Masato Muraki; Shu Imbe; Hiroshi Santo; Ryuji Sato; Hiroyuki Sano; Takashi Iwanaga; Yuji Tohda
    International archives of allergy and immunology KARGER 155 Suppl 1 (Suppl 1) 90 - 5 1018-2438 2011 [Refereed]
     
    Background: Little is known about the role of the cysteinyl leukotriene (cysLT) 2 receptor in the pathophysiology of asthma. The aim of this study is to investigate the effects of a cysLT1 receptor antagonist (montelukast) and a dual cysLT1/2 receptor antagonist (BAY-u9773) on airway hypersensitivity and airway inflammation induced by antigen challenge in ovalbumin (OVA)-sensitized guinea pigs. Methods: Male Hartley guinea pigs sensitized with OVA were intraperitoneally administered 0.1, 1, or 10 mg/kg of montelukast or 0.1 mg/kg of BAY-u9773 and then challenged with inhaled OVA. Airway reactivity to acetylcholine, inflammatory cells in bronchoalveolar lavage (BAL) fluid, and eosinophil infiltration in airway walls after OVA challenge were evaluated. Results: Pretreatment with 1 or 10 mg/kg, but not 0.1 mg/kg, of montelukast significantly suppressed airway hypersensitivity and eosinophil infiltration into the BAL fluid. Moreover, 0.1 mg/kg of BAY-u9773 significantly suppressed the development of these markers. The suppressive effects of BAY-u9773, although not significantly different, trended toward being greater than those of montelukast. Although all of the doses of montelukast tested and 0.1 mg/kg of BAY-u9773 significantly suppressed eosinophil infiltration in airway walls, the suppressive effect of BAY-u9773 was significantly greater than that of 0.1 mg/kg of montelukast. Conclusion: Signaling may contribute to the pathophysiology of asthma via the cysLT1/2 receptor. Copyright (C) 2011 S. Karger AG, Basel
  • Masato Muraki; Gerald J Gleich; Hirohito Kita
    International archives of allergy and immunology KARGER 154 (2) 119 - 27 1018-2438 2011 [Refereed]
     
    Background: Activated eosinophils are thought to play an important role in allergic inflammation. Prior reports suggest that eosinophils have receptors recognizing IgA, IgG and IgE; however, little is known regarding the direct effects of antigens and antigen-specific immunoglobulins on the functions of eosinophils. Methods: To investigate eosinophil activation by antigens mediated by the various antigen-specific immunoglobulins, we used dansyl-conjugated bovine serum albumin (DNS-BSA) and recombinant dansyl-specific antibodies (human IgG 1-4, IgA and IgE). Eosinophils from healthy donors were incubated in the wells coated with dansyl-specific immunoglobulins with or without DNS-BSA. Eosinophil activation was monitored by superoxide production and eosinophil-derived neurotoxin (EDN) release. Results: Superoxide production and EDN release by eosinophils were induced by the dansyl-specific reaction via all IgG subclasses (IgG 1-4) and IgA in the presence of DNS-BSA; the responses were not observed in the absence of antigen, DNS-BSA. The immune complexes (ICs) of DNS-BSA and dansyl-specific IgE did not induce these responses. Furthermore, IgE ICs did not enhance eosinophil activation stimulated with various immunoglobulins, IL-5 or platelet-activating factor. Conclusion: These data suggest that ICs of antigens and antigen-specific IgGs and IgA, but not IgE, in inflamed tissues may activate eosinophils and play an important role in allergic inflammation. Copyright (C) 2010 S. Karger AG, Basel
  • Masato Muraki; Yusaku Nisikawa; Eri Naito; Ryuji Sato; Takashi Iwanaga; Yuji Tohda
    The Journal of asthma : official journal of the Association for the Care of Asthma INFORMA HEALTHCARE 47 (9) 978 - 85 0277-0903 2010/11 [Refereed]
     
    Background. Little is known regarding annual changes of respiratory functions among patients with asthma after asthma symptoms enter remission. Objective. Annual changes of respiratory function and influence of patient characteristics and treatment variables on these changes were assessed in patients with adult asthma. Methods. Respiratory function (pre- and postbronchodilator forced expiratory volume in one second [FEV(1)] and reversibility by short-acting beta(2)-agonist) and their changes were retrospectively investigated and relationships between these changes, after symptomatic remission, and patient characteristics and treatments were analyzed in adult outpatients with asthma who had undergone spirometry (including a reversibility test) >= 5 times in > 5 years. Results. In patients >= 40 years old, or with disease duration >= 10 years or receiving treatment for severe asthma (steps 4-5, high-dose inhaled glucocorticosteroids, or addition of other medications), both pre- and postbronchodilator FEV(1) values were significantly lower (p < .05). Mean annual change of prebronchodilator FEV(1) (Delta pre-FEV(1)), annual change of postbronchodilator FEV(1) (Delta post-FEV(1)), and annual change of reversibility (Delta reversibility) were -13.8 +/- 59.7 ml/year, -25.9 +/- 51.0 ml/year, and -0.56% +/- 1.89%/year, respectively. Multivariate analysis after stepwise selection for variables in patient characteristics or treatments showed that disease duration >= 10 years contributed to annual improvement of respiratory functions (Delta pre-FEV(1): odds ratio [OR] 1.57, 95% confidence interval [CI] 1.01-2.46; Delta post-FEV(1): OR 2.13, 95% CI 1.25-3.66), treatment with long-acting beta(2)-agonists (LABAs) contributed to annual improvement of respiratory function (Delta pre-FEV(1): OR 2.05, 95% CI 1.23-3.16; Delta post-FEV(1): OR 1.78, 95% CI 1.11-2.87), and poor compliance contributed to annual worsening of respiratory functions (Delta pre-FEV(1): OR 0.43, 95% CI 0.24-0.76; Delta post-FEV(1): OR 0.39, 95% CI 0.22-0.70). In addition, duration of disease = 10 years and severe treatment (steps 4-5) from the beginning contributed to decreasing Delta reversibility (OR 0.55, 95% CI 0.34-0.87 and OR 0.50, 95% CI 0.29-0.83, respectively). Conclusions. Long-term treatments for asthma are expected to normalize respiratory dysfunction, which cannot be repaired in the short term. Treatment with LABAs and patient compliance may be the most important factors associated with annual improvement of respiratory functions.
  • 宮良 高維; 西川 裕作; 山藤 啓史; 忌部 周; 塚本 敬造; 宮嶋 宏之; 内藤 映理; 佐藤 隆司; 牧野 靖; 佐野 安希子; 西山 理; 山縣 俊之; 佐野 博幸; 岩永 賢司; 冨田 桂公; 村木 正人; 久米 裕昭; 東田 有智
    気管支学 (NPO)日本呼吸器内視鏡学会 32 (Suppl.) S108 - S108 0287-2137 2010/05
  • 内藤 映理; 冨田 桂公; 忌部 周; 宮嶋 宏之; 塚本 敬造; 山藤 啓史; 西川 裕作; 佐野 安希子; 佐藤 隆司; 牧野 靖; 西山 理; 山縣 俊之; 佐野 博幸; 宮良 高維; 岩永 賢司; 東本 有司; 村木 正人; 久米 裕昭; 東田 有智
    アレルギー (一社)日本アレルギー学会 59 (3-4) 376 - 376 0021-4884 2010/04
  • 佐藤 隆司; 冨田 桂公; 忌部 周; 塚本 敬造; 宮嶋 宏之; 山藤 啓史; 西川 裕作; 内藤 映理; 佐野 安希子; 牧野 靖; 西山 理; 山縣 俊之; 佐野 博幸; 宮良 高維; 岩永 賢司; 東本 有司; 村木 正人; 久米 裕昭; 東田 有智
    アレルギー (一社)日本アレルギー学会 59 (3-4) 378 - 378 0021-4884 2010/04
  • Masato Muraki; Shu Imbe; Ryuji Sato; Yoko Ikeda; Shigeyoshi Yamagata; Takashi Iwanaga; Yuji Tohda
    International immunopharmacology ELSEVIER SCIENCE BV 9 (11) 1337 - 41 1567-5769 2009/10 [Refereed]
     
    Oral cysteinyl-leukotriene (LT) receptor antagonists such as montelukast are used for reducing airway inflammation and exacerbations. However, inhaled therapy using LT receptor antagonists has not been studied. In the present study, the effect of inhaled montelukast was investigated on airway hyperresponsiveness measured by cysteinyl-LT induced bronchoconstriction in an animal model of asthma. Bronchoconstriction responses were induced by inhaled LTC4 and LTD4 (0.2 mu g/ml each) or three doses of intravenous LTC4 and LTD4 (0.3,1, 3 mu g/kg) in ovalbumin (OVA)-sensitized Hartley male guinea-pigs. The response was measured by the change in peak pressure of airway opening (Pao). The effect of montelukast was evaluated by the comparison of bronchoconstriction responses between the groups of animals pre-treated with 15-min inhalation of 10 mg/ml montelukast and saline. To evaluate the tissue injury which might be caused by montelukast inhalation, lung tissues were examined for the histology. The broncoconstriction responses induced by inhaled LTC4 and LTD4 were enhanced by OVA sensitization in the guinea-pigs. In sensitized animals, the significant increases in peak Pao were 18.5 +/- 2.1 cmH(2)O by LTC4 inhalation and 25.0 +/- 1.6 cmH(2)O by LTD4 inhalation on average. Prior treatment of inhaled montelukast potently suppressed the peak Pao increases induced by both inhaled and intravenous LTC4 and LTD4 (all P<0.01 vs. saline control). Moreover, the suppression of inhaled montelukast against LTD4-induced bronchoconstriction was observed for at least up to 24 h. According to the histological examination, montelukast inhalation produced no injury to the lung tissue. Inhaled montelukast, a cysteinyl-LT receptor antagonist, was effective in inhibiting cysteinyl-LT-induced acute bronchoconstriction, and may have the potential for clinical use as a new asthma drug. (C) 2009 Elsevier B.V. All rights reserved.
  • 冨田 桂公; 内藤 映理; 西川 裕作; 佐野 安希子; 佐藤 隆司; 山縣 俊之; 佐野 博幸; 宮良 高維; 岩永 賢司; 東本 有司; 村木 正人; 久米 裕昭; 東田 有智
    アレルギー (一社)日本アレルギー学会 58 (8-9) 1210 - 1210 0021-4884 2009/09
  • 佐藤 隆司; 冨田 桂公; 忌部 周; 塚本 敬造; 宮嶋 宏之; 山藤 啓史; 西川 裕作; 内藤 映理; 牧野 靖; 佐野 安希子; 西山 理; 山縣 俊之; 佐野 博幸; 宮良 高維; 岩永 賢司; 東本 有司; 村木 正人; 久米 裕昭; 東田 有智
    アレルギー (一社)日本アレルギー学会 58 (8-9) 1211 - 1211 0021-4884 2009/09
  • 村木 正人; 忌部 周; 山藤 啓史; 西川 裕作; 内藤 映理; 佐野 安希子; 佐藤 隆司; 山縣 俊之; 佐野 博幸; 宮良 高維; 岩永 賢司; 久米 裕昭; 冨田 桂公; 東本 有司; 東田 有智
    アレルギー (一社)日本アレルギー学会 58 (8-9) 1235 - 1235 0021-4884 2009/09
  • 山片 重良; 冨田 桂公; 宮嶋 宏之; 忌部 周; 塚本 敬造; 山藤 啓史; 西川 裕作; 内藤 映理; 市橋 秀夫; 佐野 安希子; 佐藤 隆司; 山縣 俊之; 佐野 博幸; 宮良 高維; 岩永 賢司; 村木 正人; 原口 龍太; 久米 裕昭; 東田 有智
    アレルギー (一社)日本アレルギー学会 58 (8-9) 1252 - 1252 0021-4884 2009/09
  • 内藤 映理; 冨田 桂公; 忌部 周; 宮嶋 宏之; 塚本 敬造; 山藤 啓史; 西川 裕作; 佐野 安希子; 佐藤 隆司; 山縣 俊之; 佐野 博幸; 宮良 高維; 岩永 賢司; 東本 有司; 村木 正人; 久米 裕明; 東田 有智
    アレルギー (一社)日本アレルギー学会 58 (8-9) 1256 - 1256 0021-4884 2009/09
  • 佐野 安希子; 佐野 博幸; 忌部 周; 宮嶋 宏之; 塚本 敬造; 山藤 啓史; 西川 裕作; 内藤 映理; 佐藤 隆司; 山縣 俊之; 宮良 高維; 岩永 賢司; 村木 正人; 冨田 桂公; 久米 裕昭; 東田 有智
    アレルギー (一社)日本アレルギー学会 58 (8-9) 1257 - 1257 0021-4884 2009/09
  • 宮嶋 宏之; 岩永 賢司; 塚本 敬造; 忌部 周; 山藤 啓史; 西川 裕作; 内藤 映理; 牧野 靖; 佐野 安希子; 佐藤 隆司; 西山 理; 山縣 俊之; 佐野 博幸; 宮良 高維; 冨田 桂公; 村木 正人; 久米 裕昭; 東田 有智
    アレルギー (一社)日本アレルギー学会 58 (8-9) 1282 - 1282 0021-4884 2009/09
  • Ryuji Sato; Katsuyuki Tomita; Hiroyuki Sano; Hideo Ichihashi; Shigeyoshi Yamagata; Akiko Sano; Toshiyuki Yamagata; Takayuki Miyara; Takashi Iwanaga; Masato Muraki; Yuji Tohda
    The Journal of asthma : official journal of the Association for the Care of Asthma 46 (7) 677 - 82 0277-0903 2009/09 [Refereed]
     
    BACKGROUND: Various factors have been reported to be useful for predicting future exacerbations. OBJECTIVE: This study was intended to determine a usefulness of a combination of a patient-based questionnaire, such as the Asthma Control Test (ACT) score with objective assessments, such as forced expiratory volume in 1 second (FEV(1)) and/or exhaled nitric oxide (FE(NO)), for predicting future exacerbations in adult asthmatics. METHODS: We therefore enrolled 78 subjects with mild to moderate asthma, who were clinically stable for 3 months who all had been regularly receiving inhaled steroid treatment. All subjects underwent a routine assessment of asthma control including the ACT score, spirometry, and FE(NO), and then were followed up until a severe exacerbation occurred. The predictors of an increased risk of severe exacerbation were identified and validated using decision trees based on a classification and regression tree (CART) analysis. The properties of the developed models were the evaluated with the area under the ROC curve (AUC) (95% confidence interval [CI]). RESULTS: The CART analysis automatically selected the variables and cut-off points, the ACT score
  • 中野 志仁; 山片 重良; 忌部 周; 宮嶋 宏之; 塚本 敬造; 山藤 啓史; 西川 裕作; 内藤 映理; 市橋 秀夫; 池田 容子; 佐野 安希子; 山縣 俊之; 佐藤 隆司; 佐野 博幸; 宮良 高維; 岩永 賢司; 村木 正人; 冨田 桂公; 東田 有智
    近畿大学医学雑誌 = Medical journal of Kinki University 近畿大学医学会 34 (2) 165 - 169 0385-8367 2009/06 
    [抄録]胸水貯留は胸腔内に過剰な液体が貯留する病態であり,胸水の性状より漏出性および滲出性胸水に分類される.胸水貯留の原因疾患に伴い治療方針が異なるため,鑑別が重要となる.今回我々は胸水の貯留を認め,その原因疾患の診断に苦慮した1例を経験したため,鑑別診断を中心に文献的考察を加えて報告する.
  • 村木 正人; 西川 裕作; 内藤 映理; 池田 容子; 佐野 安希子; 佐藤 隆司; 山縣 俊之; 佐野 博幸; 宮良 高維; 岩永 賢司; 冨田 桂公; 東本 有司; 東田 有智
    アレルギー (一社)日本アレルギー学会 58 (3-4) 372 - 372 0021-4884 2009/04
  • 東本 有司; 山縣 俊之; 山藤 啓史; 山片 重良; 市橋 秀夫; 内藤 映理; 西川 裕作; 佐藤 隆司; 佐野 安希子; 池田 容子; 岩永 賢司; 佐野 博幸; 宮良 高維; 冨田 桂公; 村木 正人; 東田 有智
    アレルギー (一社)日本アレルギー学会 58 (3-4) 392 - 392 0021-4884 2009/04
  • 岩永 賢司; 忌部 周; 塚本 敬造; 宮嶋 宏之; 山藤 啓史; 西川 裕作; 内藤 映理; 市橋 秀夫; 山片 重良; 佐藤 隆司; 佐野 安希子; 山縣 俊之; 佐野 博幸; 宮良 高維; 村木 正人; 冨田 桂公; 東田 有智
    アレルギー (一社)日本アレルギー学会 58 (3-4) 395 - 395 0021-4884 2009/04
  • 佐藤 隆司; 冨田 桂公; 忌部 周; 塚本 敬造; 宮嶋 宏之; 山藤 啓史; 西川 裕作; 内藤 映理; 山片 重良; 市橋 秀夫; 池田 容子; 佐野 安希子; 山縣 俊之; 佐野 博幸; 宮良 高維; 岩永 賢司; 村木 正人; 東田 有智
    アレルギー (一社)日本アレルギー学会 58 (3-4) 418 - 418 0021-4884 2009/04
  • 山縣 俊之; 山藤 啓史; 西川 裕作; 内藤 映理; 市橋 秀夫; 山片 重良; 池田 容子; 佐藤 隆司; 佐野 安希子; 岩永 賢司; 宮良 高維; 佐野 博幸; 村木 正人; 冨田 桂公; 東田 有智
    アレルギー (一社)日本アレルギー学会 58 (3-4) 422 - 422 0021-4884 2009/04
  • 佐野博幸; 冨田桂公; 渡部仁成; 佐野安希子; 市橋秀夫; 佐藤隆司; 山縣俊之; 宮良高維; 岩永賢司; 村木正人; 東田有智
    呼吸 28 (10) 0286-9314 2009
  • 宮良 高雄; 佐藤 隆司; 池田 容子; 佐野 安希子; 西川 裕作; 山片 重良; 市橋 秀夫; 山縣 俊之; 岩永 賢司; 村木 正人; 東田 有智
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 31 S131  2009
  • Masato Muraki; Hideo Ichihashi; Ryuta Haraguchi; Takashi Iwanaga; Hirokazu Kubo; Yuji Tohda
    Allergology international : official journal of the Japanese Society of Allergology Japanese Society of Allergology 57 (4) 339 - 46 1440-1592 2008/12 [Refereed]
     
    Background: The Asthma Health Questionnaire (AHQ)-Japan is useful for assessing quality of life (QOL) in Japanese patients with asthma. However, no studies have compared the AHQ-Japan to other QOL instruments. Methods: The AHQ-33-Japan and the Medical Outcomes Study Short-Form 36-Item Health Survey (SF-36) were completed simultaneously by 126 Japanese patients with asthma (48 men, 78 women 58.1 ± 17.3 years of age), and the data were compared. Results: Poor negative correlations (correlation coefficient (r) = -0.20 to -0.44, P < 0.05) were observed for 38 combinations of the subscales of these QOL instruments. As the severity of the patients' asthma increased, the scores of most subscales of both QOL instruments became worse. However, the AHQ-33 was more sensitive for severity than the SF-36. On logistic regression analysis, high Asthmatic Symptoms, Factors which Worsened Symptoms, Emotion, Daily Activity, and Social Activity subscale scores, as well as a high total 32-item score, of the AHQ-33 were associated with an increased risk of moderate to severe asthma. On the other hand, only the Physical functioning subscale score of the SF-36 was associated with an increased risk of moderate to severe asthma. Conclusions: Our results show that the AHQ-33 is useful as a disease-specific QOL instrument in Japanese patients with asthma and that it is better than the SF-36, which is a generic QOL instrument. In the future, the AHQ-33 should be compared to other asthma-specific questionnaires. © 2008 Japanese Society of Allergology.
  • 山片 重良; 冨田 桂公; 佐藤 隆司; 山藤 啓史; 西川 裕作; 内藤 映理; 市橋 秀夫; 池田 容子; 佐野 安希子; 山縣 俊之; 佐野 博幸; 岩永 賢司; 村木 正人; 東田 有智
    アレルギー (一社)日本アレルギー学会 57 (9-10) 1418 - 1418 0021-4884 2008/10
  • 佐藤 隆司; 冨田 桂公; 山藤 啓史; 西川 裕作; 内藤 映理; 市橋 秀夫; 山片 重良; 池田 容子; 佐野 安希子; 山縣 俊之; 佐野 博幸; 宮良 高維; 岩永 賢司; 村木 正人; 東田 有智
    アレルギー (一社)日本アレルギー学会 57 (9-10) 1451 - 1451 0021-4884 2008/10
  • 市橋 秀夫; 佐野 博幸; 山藤 啓史; 西川 裕作; 内藤 映理; 山片 重良; 池田 容子; 佐野 安希子; 佐藤 隆司; 山縣 俊之; 宮良 高維; 岩永 賢司; 村木 正人; 冨田 桂公; 東田 有智
    アレルギー (一社)日本アレルギー学会 57 (9-10) 1452 - 1452 0021-4884 2008/10
  • 佐野 博幸; 市橋 秀夫; 西川 裕作; 山藤 啓史; 内藤 映理; 山片 重良; 池田 容子; 佐野 安希子; 佐藤 隆司; 山縣 俊之; 宮良 高維; 岩永 賢司; 村木 正人; 冨田 桂公; 東田 有智
    アレルギー (一社)日本アレルギー学会 57 (9-10) 1480 - 1480 0021-4884 2008/10
  • 佐野 安希子; 佐野 博幸; 山藤 啓史; 西川 裕作; 内藤 映理; 市橋 秀夫; 山片 重良; 池田 容子; 佐藤 隆司; 山縣 俊之; 宮良 高維; 岩永 賢司; 村木 正人; 冨田 桂公; 東田 有智
    アレルギー (一社)日本アレルギー学会 57 (9-10) 1482 - 1482 0021-4884 2008/10
  • 西川 裕作; 佐野 博幸; 山藤 啓史; 宮嶋 宏之; 忌部 周; 塚本 敬造; 内藤 映理; 市橋 秀夫; 山片 重良; 池田 容子; 佐野 安希子; 佐藤 隆司; 宮良 高維; 岩永 賢司; 村木 正人; 冨田 桂公; 東田 有智
    近畿大学医学雑誌 近畿大学医学会 33 (3) 14A - 14A 0385-8367 2008/09
  • M. Muraki; S. Kitaguchi; H. Ichihashi; R. Haraguchi; T. Iwanaga; H. Kubo; A. Higashiyama; Y. Tohda
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH FIELD HOUSE PUBLISHING LLP 36 (5) 906 - 913 0300-0605 2008/09 [Refereed]
     
    This study investigated the differences in apnoea-hypopnoea index (AHI) during rapid eye movement (REM) sleep (AHI-REM) and AHI during non-REM (NREM) sleep (AHI-NREM) in patients with obstructive sleep apnoea (OSA). Nocturnal polysomnography was performed in 102 Japanese OSA patients and their AHI along with a variety of other factors were retrospectively evaluated. Regardless of the severity of AHI, mean apnoea duration was longer and patients' lowest recorded oxygen saturation measured by pulse oximetry was lower during REM sleep than during NREM sleep. Approximately half of the patients (n = 50) had a higher AHI-NREM than AHI-REM. in subjects with AHI >= 60 events/h, AHI-NREM was significantly higher than AHI-REM. On multivariate logistic regression, severe AHI >= 30 events/h was the only predictor of a higher AHI-NREM than AHI-REM. This may indicate that important, but unknown, factors related to the mechanism responsible for the severity of OSA are operative during NREM sleep.
  • 山片 重良; 冨田 桂公; 西川 裕作; 内藤 映理; 市橋 秀夫; 池田 容子; 佐藤 隆司; 佐野 安希子; 佐野 博幸; 宮良 高維; 岩永 賢司; 村木 正人; 東田 有智
    呼吸 (一社)呼吸研究 27 (5) 518 - 520 0286-9314 2008/05
  • 村木 正人; 西川 裕作; 内藤 映理; 市橋 秀夫; 山片 重良; 池田 容子; 佐野 安希子; 佐藤 隆司; 辻 文生; 佐野 博幸; 岩永 賢司; 宮良 高維; 冨田 桂公; 久保 裕一; 東田 有智
    日本呼吸器学会雑誌 (一社)日本呼吸器学会 46 (増刊) 146 - 146 1343-3490 2008/05
  • M. Muraki; T. Iwanaga; R. Haraguchi; H. Kubo; Y. Tohda
    INTERNATIONAL IMMUNOPHARMACOLOGY ELSEVIER SCIENCE BV 8 (5) 725 - 731 1567-5769 2008/05 [Refereed]
     
    It is unclear whether inhaled lidocaine is effective against airway hyperreactivity and inflammation in asthma. The aim of this study was to investigate the effects of inhaled lidocaine on airway hyperreactivity and inflammation. Airway reactivity to inhaled histamine, cellular composition of bronchoalveolar lavage (BAL) fluid, plasma substance P (SP), and isolated lung tissue were evaluated in ovalbumin (OVA)-sensitized guinea pigs 7 days after OVA challenge. The effects of inhaled lidocaine on this model were also evaluated. Treatment with lidocaine was administered in two fashions: as single inhalation or inhalation bid for 7 consecutive days, for comparison with a saline-inhaled control group. Airway hyperreactivity to histamine, increase in number of total cells and increased proportion of eosinophils in BAL fluid, and marked eosinophil infiltration in airway walls were noted even 7 days after OVA challenge in the control group. Plasma SP level was also significantly increased. Although treatment with single lidocaine inhalation did not affect airway hyperreactivity, continued inhalation (bid for 7 days) attenuated airway hyperreactivity. Continued, but not single, inhalation of lidocaine also suppressed infiltration of eosinophils in BAL fluid and in airway walls. In addition, plasma SP levels were significantly reduced by continued but not by single inhalation. It appears possible that lidocaine when inhaled suppresses eosinophilic inflammation of the airway and SP-induced neurogenic inflammation, leading to alleviation of airway hyperreactivity. (c) 2008 Elsevier B.V. All rights reserved.
  • 宮良高維; 上田朋子; 佐藤隆司; 池田容子; 内藤映理; 山片重良; 市橋秀夫; 佐野安希子; 佐野博幸; 岩永賢司; 村木正人; 久保裕一; 東田有智
    日本呼吸器学会雑誌 45 1343-3490 2007
  • 村木正人; 村木正人; 市橋秀夫; 北口佐也子; 原口龍太; 大森隆; 辻文生; 佐野博幸; 宮良高維; 岩永賢司; 久保裕一; 東田有智
    アレルギー 56 (3/4) 0021-4884 2007
  • 佐野博幸; 冨田桂公; 西川裕作; 内藤映理; 山片重良; 市橋秀夫; 池田容子; 佐野安希子; 佐藤隆司; 宮良高維; 岩永賢司; 村木正人; 原口龍太; 久保裕一; 久保裕一; 東田有智
    アレルギー 56 (8/9) 0021-4884 2007
  • 岩永賢司; 佐藤隆司; 西川裕作; 内藤映理; 池田容子; 佐野安希子; 佐野博幸; 宮良高維; 村木正人; 富田桂公; 東田有智; 久保裕一
    アレルギー 56 (8/9) 0021-4884 2007
  • 村木 正人; 西川 裕作; 内藤 映理; 市橋 秀夫; 山片 重良; 池田 容子; 佐野 安希子; 佐藤 隆司; 辻 文生; 佐野 博幸; 宮良 高雄; 岩永 賢司; 冨田 桂公; 久保 裕一; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 56 (8) 1122 - 1122 2007
  • 小児から成人へのアレルギー疾患移行とその阻止 —大規模調査から—
    村木正人; 東田有智
    臨床免疫・アレルギー科 47 (1) 47 - 54 2007
  • 下大静脈欠損・奇静脈結合を伴った急性肺血栓塞栓症の一例
    北口 佐也子; 宮良 高維; 上田 朋子; 辻 文生; 佐野 博幸; 岩永 賢司; 村木 正人; 久保 裕一; 東田 有智
    日本呼吸器学会 44 (12) 957 - 961 2006/12
  • Sayako Kitaguchi; Takayuki Miyara; Tomoko Ueda; Fumio Tsuji; Hiroyuki Sano; Takashi Iwanaga; Masato Muraki; Hirokazu Kubo; Yuji Tohda
    Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 12 44 (12) 957 - 61 1343-3490 2006/12 [Refereed]
     
    A 38-year-old man with atopic dermatitis presented with right chest pain and dyspnea. Previously, he had received 2mg of betamethasone daily, to prevent rejection of the right transplanted cornea, for 24 days. His body temperature was 37.4 degrees C, peripheral leucocyte count measured 12,000/mm3, and C-reactive protein was 6.3 mg/dl. A computed tomogram of the chest revealed infiltration in the right lower lung field, and he was then treated for pneumonia. The second day he fell down one flight of stairs due to a syncopal attack and received a head injury. At this point his vital blood pressure was 102/55 mmHg, heart rate was 130/min and SpO2 under breathing room air was 76%. These findings indicated possible acute pulmonary thromboembolism. Enhanced computed tomography revealed pulmonary arteries occluded by massive thrombosis and anomalous inferior vena cava with azygous continuation. To decrease the risk of further cerebral bleeding, anti-coagulation therapy was administered with only 24,000 IU/day of heparin. Following treatment, the patient completely recovered. We reported this rare case of acute pulmonary thromboembolism accompanied by anomalous inferior vena cava with azygous continuation.
  • 村木 正人; 市橋 秀夫; 山片 重良; 池田 容子; 北口 佐也子; 山藤 緑; 佐野 安希子; 辻 文生; 佐野 博幸; 宮良 高維; 岩永 賢司; 原口 龍太; 久保 裕一; 東田 有智
    日本呼吸器学会雑誌 (一社)日本呼吸器学会 44 (増刊) 259 - 259 1343-3490 2006/06
  • Masato Muraki; Sayako Kitaguchi; Hideo Ichihashi; Fumio Tsuji; Takashi Ohmori; Ryuta Haraguchi; Yuji Tohda
    Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 44 (6) 425 - 30 1343-3490 2006/06 
    Our medical institution does not have a bacterial culture facility, requiring outsourcing of bacterial culture tests. Due to the time elapsed from the time of specimen collection to culturing, the identification of causative bacteria in respiratory tract infections tends to be difficult. We therefore used transport medium for sputum bacteria examinations. Expectorated purulent or purulent-mucous sputum specimens were collected from 32 patients with lower respiratory tract infection. We divided each of the sputum specimens into the two treatment groups: transport medium (Seedswab gamma2) ndar and stad disinfection container. Paired samples prepared from each patient were sent out for bacterial culture together. The time elapsed from collection to delivery to the lab were as follows: day 0 (same day, n = 14 patients), day 1 (n = 15), day 2 (n = 2), and day 3 (n = 1). The identified causative bacteria were Streptococcus pneumoniae (n = 6 patients), Haemophilus influenzae (n =5), Pseudomonas aeruginosa (n = 4), Staphylococcus aureus (n = 2), Moraxella catarrhalis (n = 2), Klebsiella pneumoniae (n = 1), and Streptococcus agalactiae (n = 1). Samples prepared by each of the two methods gave similar results. The utility of transport medium for examination of general bacteria for lower airway infection from sputum samples was not demonstrated. The rate of detection of bacteria decreased, when the transport of samples was delayed. Therefore, we need to send the sputum specimens as quickly as possible.
  • 日本語版Asthma Control Test:喘息コントロールテストによる喘息コントロール状態の判定に関する有用性の検討
    東田 有智; 久保 裕一; 村木 正人; 岩永 賢司; 宮良 高維; 佐野 博幸
    アレルギー・免疫 医薬ジャーナル社 13 (5) 72 - 79 2006/05
  • 久保 裕一; 内藤 映理; 山片 重良; 市橋 秀夫; 山藤 緑; 池田 容子; 北口 佐也子; 辻 文生; 佐野 安希子; 佐野 博幸; 宮良 高維; 岩永 賢司; 村木 正人; 東田 有智
    アレルギー (一社)日本アレルギー学会 55 (3-4) 432 - 432 0021-4884 2006/04
  • 岩永 賢司; 森富 美子; 内藤 映理; 池田 容子; 佐野 博幸; 宮良 高維; 村木 正人; 久保 裕一; 東田 有智; 辻 文生
    アレルギー 一般社団法人 日本アレルギー学会 55 (8) 1095 - 1095 2006
  • 山藤 緑; 岩永 賢司; 辻 文生; 佐野 博幸; 宮良 高維; 村木 正人; 久保 裕一; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 55 (3) 430 - 430 2006
  • 池田 容子; 佐野 博幸; 市橋 秀夫; 山片 重良; 内藤 映理; 北口 佐也子; 佐野 亜希子; 佐藤 隆司; 宮良 高維; 岩永 賢司; 村木 正人; 久保 裕一; 東田 万智; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 55 (8) 1173 - 1173 2006
  • 佐野 博幸; 市橋 秀夫; 宮良 高維; 岩永 賢司; 村木 正人; 久保 裕一; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 55 (3) 358 - 358 2006
  • 村木 正人; 市橋 秀夫; 北口 佐也子; 原口 龍太; 大森 隆; 岩永 賢司; 久保 裕一; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 55 (8) 1130 - 1130 2006
  • 久保 裕一; 坂本 直哉; 西川 裕作; 市橋 秀夫; 山片 重良; 内藤 映理; 佐野 安希子; 北口 佐也子; 池田 容子; 佐藤 隆司; 佐野 博幸; 宮良 高雄; 岩永 賢司; 村木 正人; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 55 (8) 1209 - 1209 2006
  • 近畿大学附属病院における成人気管支喘息患者のQOL調査
    森富美子; 岩永賢司; 辻文生; 佐野博幸; 宮良高維; 村木正人; 久保裕一; 東田有智
    近畿大学医学雑誌 31 123 - 129 2006 [Refereed]
  • Hirokazu Kubo; Noritsugu Honda; Fumio Tsuji; Takashi Iwanaga; Masato Muraki; Yuji Tohda
    Asia Pacific journal of clinical nutrition 4 15 (4) 551 - 5 0964-7058 2006 [Refereed]
     
    Recently, efforts in comprehensive pulmonary rehabilitation for COPD have been made, including education, physical therapy, occupational therapy, nutrition, nursing, medication and counseling. Each patient focuses on a different element. Supplying adequate nutrition, among others, is essential for comprehensive pulmonary rehabilitation, as well as survival. In this study, the utility of efficient nutritional supplement therapy before and after pulmonary physical therapy was investigated by adding an amino acid drink with a high Fisher ratio to comprehensive pulmonary rehabilitation. The subjects were eight patients with COPD with obstructive ventilation disorder as severe as 31.5 +/- 6% of FEV 1.0%. Pulmonary physical therapy was performed for eight weeks in a group administered one bottle of dietary supplement with a high Fisher ratio abundant in branched chain amino acids once daily (200 kCal/ 200 mL, Fisher ratio 40), and in another group without administration. Before and after the physical therapy, six-minute waking examination, QOL assessment (using CRQ), serum protein and serum Fisher ratio were comparatively examined between the two groups. After the eight weeks of pulmonary physical therapy, serum Fisher ratios were evidently reduced and serum protein measurements were also decreased in the group without dietary supplement abundant in branched chain amino acids. Accordingly, more amino acid is needed due to enhanced consumption of muscular protein during pulmonary physical therapy, during which nutrient ingestion including a sufficient amount of branched amino acid is necessary. It is an important element in continuing comprehensive pulmonary rehabilitation for a longer period.
  • 内藤 映理; 岩永 賢司; 山片 重良; 市橋 秀夫; 池田 容子; 北口 佐也子; 大森 隆; 上田 朋子; 山藤 緑; 佐藤 隆司; 佐野 安希子; 辻 文生; 佐野 博幸; 宮良 高維; 村木 正人; 原口 龍太; 久保 裕一; 東田 有智
    近畿大学医学雑誌 近畿大学医学会 30 (2) 43A - 43A 0385-8367 2005/11
  • 辻 文生; 市橋 秀夫; 池田 容子; 大森 隆; 上田 朋子; 山藤 緑; 佐藤 隆司; 佐野 博幸; 宮良 高維; 岩永 賢司; 村木 正人; 原口 龍太; 久保 裕一; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 54 (3) 388 - 388 2005
  • 岩永 賢司; 辻 文生; 佐野 博幸; 宮良 高維; 村木 正人; 原口 龍太; 久保 裕一; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 54 (8) 951 - 951 2005
  • 村木正人; 北口佐也子; 市橋秀夫; 辻文生; 宮良高維; 原口龍太; 東田有智
    日本呼吸器学会雑誌 43 1343-3490 2005
  • 村木 正人; 辻 文生; 岩永 賢司; 原口 龍太; 久保 裕一; 東田 有智; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 53 (2) 348 - 348 2004
  • 森 富美子; 東田 有智; 辻 文生; 岩永 賢司; 村木 正人; 原口 龍太; 久保 裕一
    アレルギー 一般社団法人 日本アレルギー学会 52 (2) 320 - 320 2003
  • 村木 正人; 上田 朋子; 森 富美子; 辻 文生; 川合 右展; 岩永 賢司; 原口 龍太; 久保 裕一; 中島 重徳; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 52 (2) 315 - 315 2003
  • 辻 文生; 東田 有智; 山片 重良; 市橋 秀夫; 森 富美子; 岩永 賢司; 村木 正人; 原口 龍太; 久保 裕一; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 52 (2) 353 - 353 2003
  • 山片 重良; 岩永 賢司; 市橋 秀夫; 上田 朋子; 森 富美子; 辻 文生; 村木 正人; 原口 龍太; 久保 裕一; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 52 (2) 352 - 352 2003
  • 岩永 賢司; 原口 龍太; 市橋 秀夫; 山片 重良; 上田 朋子; 森 富美子; 辻 文生; 村木 正人; 久保 裕一; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 52 (2) 366 - 366 2003
  • 久保 裕一; 東田 有智; 山上 富美子; 辻 文生; 川合 右展; 澤口 博千代; 岩永 賢司; 村木 正人; 原口 龍太; 福岡 正博; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 51 (2) 245 - 245 2002
  • 辻 文生; 森 富美子; 川合 右展; 岩永 賢司; 村木 正人; 原口 龍太; 久保 裕一; 東田 有智; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 51 (9) 911 - 911 2002
  • 原口 龍太; 東田 有智; 市橋 秀雄; 嶋 あゆみ; 山片 重良; 上田 朋子; 森 富美子; 辻 文生; 岩永 賢司; 村木 正人; 久保 裕一
    アレルギー 一般社団法人 日本アレルギー学会 51 (9) 915 - 915 2002
  • 森 富美子; 東田 有智; 市橋 秀雄; 嶋 あゆみ; 山片 重良; 上田 朋子; 辻 文生; 岩永 賢司; 村木 正人; 原口 龍太; 久保 裕一; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 51 (9) 967 - 967 2002
  • 村木 正人; 上田 朋子; 森 富美子; 辻 文生; 川合 右展; 岩永 賢司; 原口 龍太; 久保 裕一; 中島 重徳; 東田 有智
    アレルギー 一般社団法人 日本アレルギー学会 51 (9) 1001 - 1001 2002
  • 辻 文生; 東田 有智; 川合 右展; 澤口 博千代; 岩永 賢司; 村木 正人; 原口 龍太; 久保 裕一; 福岡 正博; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 50 (2) 334 - 334 2001
  • 原口 龍太; 東田 有智; 辻 文生; 川合 右展; 岩永 賢司; 村木 正人; 久保 裕一; 福岡 正博; 中島 重徳
    Japanese Journal of Allergology Japanese Society of Allergology 50 (2) 227 - 227 2001
  • 原口 龍太; 東田 有智; 山上 富美子; 辻 文生; 川合 右展; 沢口 博千代; 岩永 賢司; 村木 正人; 久保 裕一; 福岡 正博; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 50 (9) 988 - 988 2001
  • Y Tohda; M Muraki; H Kubo; M Itoh; R Haraguchi; S Nakajima; M Fukuoka
    RESPIRATION KARGER 68 (1) 73 - 77 0025-7931 2001/01 [Refereed]
     
    Background: Airway hyperresponsiveness (AHR) is one of the characteristic features of hu man asthma. The presence of AHR and the precise mechanisms immediately after establishment of sensitization in guinea pigs are unclear, although there are many reports showing allergen exposure that causes an increase in bronchial responsiveness associated with eosinophil influx into the airway in sensitized guinea pigs. Objective: We investigated the inhibitory effects on AHR to histamine of ONO-1078, a leukotriene antagonist; indomethacin, a cyclooxygenase inhibitor; S-145, a thromboxane A(2) (TXA(2)) antagonist, and Y-24180, a platelet-activating factor (PAF) antagonist, to assess the involvement of chemical mediators in AHR employing ovalbumin (OA) sensitized guinea pig models. Methods: Male Hartley guinea pigs were used. Each group comprised 4-7 animals. The animals were sensitized to OA, injecting intraperitoneally 30 mg of cyclophosphamide and 2,000 mug of OA together with 100 mg of aluminum hydroxide as the adjuvant. The guinea pigs were artificially ventilated via a cannula using a smalt-animal respirator after intraperitoneal anesthesia with pentobarbital sodium for tracheotomy. The pressure at the airway opening (PAO) was measured using a differential pressure transducer, and a differential pressure of peak PAO (peak Delta PAO) at inspiratory phase as an overall index of bronchial response to bronchoactive agents was used. While being artificially ventilated, the animals were exposed to physiological saline solution containing various concentrations of histamine (4.9, 9.8, 20, 39, 78, and 156 mug/ml) by inhalation for 30 s at 3-min intervals. Determinations were made at 1 min after each inhalation. The chemical mediators were each (30 mg/kg of ONO-1078, 3 mg/kg of S-1452, and 1 mg/kg of Y-24180) administered orally to sensitized guinea pigs, and the airway response to histamine was assessed. Each group comprised 4-7 animals. Results: The airway response to histamine was significantly greater in the sensitized group than in the nonsensitized group at histamine concentrations of 36 (p < 0.05), 78, and 156 mg/ml (p < 0.01). Leukotrienes C-4 and D-4: 30 mg/kg of ONO-178 did not show any inhibitory effect on airway response to inhaled histamine. Cyclooxygenase: 5 mg/kg of indomethacin did not show any inhibitory effect on the airway response to inhaled histamine. TXA(2): the AHR to inhaled histamine at doses of 9.8, 39, 78, and 156 mug/ml was significantly inhibited by prior administration of 3 mg/kg of S-1452. PAF: the AHR to inhaled histamine at doses of 9.8, 39, and 78 mug/ml was significantly inhibited by prior administration of 1 mg/kg of Y-24180. Conclusions: S-1452 (3 mg/kg) and V-24180 (1 mg/kg) significantly inhibited AHR to histamine, while ONO-108 (30 mg/kg) and indomethacin (5 mg/kg) did not. The results suggest that TXA(2) and PAF are involved in AHR in OA-sensitized guinea pigs. Copyright(C)2001 S. Karger AG, Basel.
  • Effect of AA-2414 on Early and Late Bronchial Responses in Actively Sensitized Guineda-pigs
    Tohda Y; Muraki M; Kubo H; Iwanaga T; Nakajima S; Fukuoka M
    The Journal of International Medical Research 29 29 - 35 2001 [Refereed]
  • Y Tohda; M Muraki; T Iwanaga; R Haraguchi; M Fukuoka; S Nakajima
    ALLERGY AND ASTHMA PROCEEDINGS OCEAN SIDE PUBLICATIONS INC 21 (2) 79 - 84 1088-5412 2000/03 [Refereed]
     
    The authors have successfully developed an animal model of dual-phase bronchial responses and very high IgG titer by sensitizing Hartley-strain male guinea pigs. Specific airway resistance, which was determined in a two-chamber body plethysmograph, was elevated to sevenfold during immediate response, followed by a late phase response with a smaller but marked elevation in resistance. Furthermore, hematological and histological examinations revealed that the total cell count increased in BAL obtained during both immediate and late bronchial responses as compared to pre-OVA challenges. A,significant increase in BAL eosinophils was present only for the late bronchial samples, and this finding was supported by histological examination.
  • Y Tohda; M Muraki; A Kawai; T Iwanaga; H Kubo; M Fukuoka; S Nakajima
    INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY PERGAMON-ELSEVIER SCIENCE LTD 22 (2) 123 - 130 0192-0561 2000/02 [Refereed]
     
    The effects of an oral anti-allergic agent, TMK-688, which inhibits 5-lipoxygenase, at doses of 3.2 and 10 mg/kg were studied in guinea pigs with dual-phase asthmatic response. We previously observed that pretreatment with TMK-688 inhibited the late asthmatic response (LAR) induced-by ovalbumin inhalation exposure. The present study focused on the effect of TMK-688 on infiltration by T-cells and eosinophils. TMK-688 inhibited both T-cell and eosinophilic infiltration. These findings suggest that TMK-688 is effective in inhibiting infiltration of T-cells and eosinophilic chemotaxis, and thereby suppresses LAR. (C) 2000 International Society for Immunopharmacology. Published by Elsevier Science Ltd. All rights reserved.
  • 辻 文生; 東田 有智; 川合 右展; 澤口 博千代; 岩永 賢司; 村木 正人; 原田 龍太; 久保 裕一; 福岡 正博; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 49 (2) 234 - 234 2000
  • 川合 右展; 東田 有智; 辻 文生; 澤口 博千代; 岩永 賢司; 村木 正人; 原口 龍太; 久保 裕一; 福岡 正博; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 49 (2) 287 - 287 2000
  • 澤口 博千代; 東田 有智; 辻 文生; 川合 右展; 岩永 賢司; 浦上 理恵; 村木 正人; 原口 龍太; 久保 裕一; 福岡 正博; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 49 (2) 211 - 211 2000
  • 原口 龍太; 東田 有智; 辻 文生; 川合 右展; 沢口 博千代; 岩永 賢司; 浦上 理恵; 村木 正人; 久保 裕一; 福岡 正博; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 49 (9) 927 - 927 2000
  • 久保 裕一; 東田 有智; 辻 文生; 川合 右展; 澤口 博千代; 岩永 賢司; 村木 正人; 原口 龍太; 福岡 正博; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 49 (9) 926 - 926 2000
  • 村木 正人; 東田 有智; 福岡 正博; 中島 重徳; 紀太 博仁; Gleich GJ
    アレルギー 一般社団法人 日本アレルギー学会 49 (2) 256 - 256 2000
  • 原口 龍太; 東田 有智; 辻 文生; 川合 右展; 澤口 博千代; 岩永 賢司; 村木 正人; 久保 裕一; 福岡 正博; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 49 (9) 893 - 893 2000
  • Y Tohda; R Haraguchi; H Kubo; M Muraki; M Fukuoka; S Nakajima
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY PROUS SCIENCE, SA 21 (6) 449 - 452 0379-0355 1999/07 [Refereed]
     
    In recent years, bronchial asthma has come to be regarded pathologically as a chronic inflammatory disease of the respiratory tract. Inhalational steroids and antiinflammatory drugs are recognized as being effective against bronchial asthma. In this study, the effects of Saiboku-to, a Chinese her bal (Kampo) formulation, were investigated on asthmatic guinea pigs sensitized to ovalbumin (OA). Following 7-day administration of Saiboku-to (500 mu g/kg), the late asthmatic response (LAR) to an antigen challenge was found to be inhibited. The number of eosinophils in fluid obtained by bronchoalveolar lavage (BAL) 4 h after antigen challenge was decreased while the infiltration of eosinophils and T-lymphocytes into the lung parenchyma was inhibited. These findings suggest that Saiboku-to has the potential to become a useful drug in the treatment of bronchial asthma. (C)1999 Prous Science. All rights reserved.
  • Y Tohda; R Haraguchi; H Kubo; M Muraki; M Fukuoka; S Nakajima
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY PROUS SCIENCE, SA 21 (5) 327 - 330 0379-0355 1999/06 [Refereed]
     
    In recent years, bronchial asthma has come to be regarded as a chronic inflammatory disease of the respiratory tract, with mast cells, lymphocytes and eosinophils playing important roles in its pathogenesis. Proteins contained in eosinophil granules, especially major basic protein (MBP), eosinophil cationic protein (ECP), eosinophil-derived neurotoxin (EDN) and eosinophil peroxidase (EPO), can cause tissue injury. When stimulated, eosinophils release mediators such as leukotriene C-4 (LTC4) and platelet activating factors (PAF). Thus, they are recognized as effector cells that are actively involved in the development of allergic inflammation. In this study, eosinophils from healthy volunteers were used to investigate the effects of Saiboku-to on eosinophils whose survival had been prolonged through stimulation with eosinophil-activating cytokines such as interleukin (IL)-3, IL-5 and granulocyte macrophage colony stimulating factors (GM-CSF). As a result, the cytokine-enhanced survival of eosinophils was significantly shortened by the addition of Saiboku-to. These findings suggest that Saiboku-to has the potential to inhibit allergic responses by directly affecting eosinophils which are related to allergic inflammation. (C)1999 Prous Science. All rights reserved.
  • 原口 龍太; 東田 有智; 辻 文生; 川合 右展; 沢口 博千代; 仲原 弘; 岩永 賢司; 浦上 理恵; 村木 正人; 久保 裕一; 福岡 正博; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 48 (8) 949 - 949 1999
  • 澤口 博千代; 東田 有智; 辻 文生; 川合 右展; 仲原 弘; 岩永 賢司; 浦上 理恵; 村木 正人; 原口 龍太; 久保 裕一; 福岡 正博; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 48 (8) 1059 - 1059 1999
  • 久保 裕一; 東田 有智; 川合 右展; 辻 文生; 澤口 博千代; 仲原 弘; 岩永 賢司; 村木 正人; 浦上 理恵; 原口 龍太; 福岡 正博; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 48 (8) 985 - 985 1999
  • 澤口 博千代; 東田 有智; 川合 右展; 仲原 弘; 岩永 賢司; 浦上 理恵; 村木 正人; 原口 龍太; 久保 裕一; 福岡 正博; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 48 (2) 303 - 303 1999
  • 原口 龍太; 東田 有智; 川合 右展; 沢口 博千代; 仲原 弘; 浦上 理恵; 岩永 賢司; 村木 正人; 久保 裕一; 福岡 正博; 中島 重徳
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 21 (3) 188 - 188 1999
  • 川合 右展; 東田 有智; 澤口 博千代; 岩永 賢司; 村木 正人; 原口 龍太; 久保 裕一; 福岡 正博; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 48 (2) 316 - 316 1999
  • Applicability of Ureteropelvic Fiberscopy in the Diagnosis of Peripheral Lung Cancer
    Yuji Tohda; Masato Muraki; Takashi Iwanaga; Hirokazu Kubo; Ryuta Haraguchi; Masahiro Fukuoka
    Journal of Bronchology 6 251 - 256 1999 [Refereed]
  • Y Tohda; M Muraki; H Kubo; S Nakajima; M Fukuoka; A Watanabe
    GENERAL PHARMACOLOGY PERGAMON-ELSEVIER SCIENCE LTD 31 (2) 323 - 328 0306-3623 1998/08 [Refereed]
     
    1. The effect of a new antiasthmatic drug, TYB-2285 [3,5-bis (acetoxyacetylamino)-4-chlorobenzonitrile], on dual bronchoconstriction and airway hyperreactivity in actively sensitized guinea pigs was investigated. 2. Immediate and late bronchial responses were induced at 1-10 min and 4-7 hr after antigen inhalation, respectively. Guinea pigs were pretreated with TYB-2285 (300 mg kg(-1) PO, as a single dose or consecutively for 7 days). 3. The immediate bronchial response was inhibited only by a multiple administration of TYB-2285. Late bronchial response was inhibited by both administration methods. 4. The numbers of eosinophils, neutrophils and macrophages, but not lymphocytes, in the bronchoalveolar lavage fluid were increased at 4 hr after antigen inhalation. TYB-2285, given singly and consecutively, decreased the numbers of total cells, eosinophils, neutrophils and macrophages. 5. Sensitized guinea pigs showed significant airway hyperreactivity to inhaled histamine. This airway hyperresponsiveness was reversed by a single administration of TYB-2285. 6. Luminol dependent chemiluminescence of airway-infiltrated cells was slightly inhibited by TYB-2285 (20 mu g ml(-1)). 7. The present study shows that TYB-2285 inhibits late asthmatic response and airway hyperresponsiveness, presumably by inhibiting the accumulation and activation of eosinophils and other inflammatory cells. (C) 1998 Elsevier Science Inc.
  • Y Tohda; K Ohkawa; H Kubo; M Muraki; M Fukuoka; S Nakajima
    CLINICAL AND EXPERIMENTAL ALLERGY BLACKWELL SCIENCE LTD 28 (6) 772 - 777 0954-7894 1998/06 [Refereed]
     
    Background gamma-Aminobutyric acid (GABA), an important inhibitory neurotransmitter in the mammalian central nervous system, is also found in peripheral tissues, including the lung. GABA has recently been shown to modulate the contraction of airway smooth muscle. Objective We studied the effect of GABA on the contractile properties of tracheal smooth muscle by measuring the tension of the trachea isolated from non-sensitized and ovalbumin (OA)-sensitized guinea-pigs under isometric conditions. Methods Guinea-pigs were sensitized by intraperitoneal doses of OA to prepare a bronchial asthma model. Tracheal spiral rings were prepared from the OA-sensitized as well as normal, non-sensitized guinea-pigs. Using the tracheal preparations, the effects of GABA and GABAa and GABAb receptor agonists (muscimol and baclofen) and antagonists (bicuculline and saclofen) on the basal tone of the trachea and on tracheal contraction induced by electrical field stimulation (EFS) were determined. The effect of GABA on tracheal contraction induced by exogenous acetylcholine was also studied. Results GABA and GABA agonists and antagonists had no effect on the basal tone of normal guinea-pig tracheae. Both GABAa and GABAb receptor agonists, as well as GABA, suppressed EFS-induced contraction of normal guinea-pig tracheae in a reversible, dose-dependent manner. Moreover, this suppression was reserved to the control level by either GABAa and GABAb receptor antagonists. In tracheal spiral ring prepared from OA-sensitized guinea-pigs, GABA and baclofen caused a smaller reversible inhibition of EFS-induced contraction than in normal tracheal spiral ring, while muscimol inhibited EFS-induced tracheal contraction to a similar extent to that observed in normal tracheae. GABA had no effect on the tracheal contractile response to acetylcholine. Conclusion The results suggest that there may be a biological mechanism mediated by prejunctional GABAb receptors which attenuates cholinergic contraction of airway smooth muscle and that dysfunction of the receptors may underlie the airway obstruction in asthmatics.
  • Y Tohda; M Muraki; T Iwanaga; H Kubo; M Fukuoka; S Nakajima
    INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY PERGAMON-ELSEVIER SCIENCE LTD 20 (4-5) 173 - 181 0192-0561 1998/04 [Refereed]
     
    It was recently reported that theophylline has an anti-inflammatory and bronchodilating effect on bronchial asthma. Accordingly, to examine the anti-inflammatory effect of theophylline on asthma, especially its effect on eosinophil activation, a sustained-release theophylline preparation (Theolong(R)) was administered (daily dose; 400 mg) to 18 patients with mild to moderate bronchial asthma. This was done in order to study the preparation's effects on lung function, blood and sputum eosinophils and ECP four weeks pre- and postadministration. Lung function was determined by spirometry and sputum by induced sputum. Blood and sputum ECP levels were determined using an ECP RTA kit. In lung function, there were no differences in vital capacity (VC) or in forced expiratory volume 1 s (FEV 1.0) pre- and post-administration. There were also no differences in the number of blood and sputum eosinophils, but serum and sputum ECP levels decreased. Theophylline is thus expected to exert an inhibitory effect on eosinophil activation and it is suggested as an effective therapeutic drug for bronchial asthma. (C) 1998 International Society for Immunopharmacology. Published by Elsevier Science Ltd.
  • 沢口 博千代; 東田 有智; 川合 右展; 仲原 弘; 岩永 賢司; 村木 正人; 原口 龍太; 久保 裕一; 福岡 正博; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 47 (2) 328 - 328 1998
  • 沢口 博千代; 東田 有智; 河合 右展; 仲原 弘; 岩永 賢司; 村木 正人; 原口 龍太; 久保 裕一; 福岡 正博; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 47 (9) 1107 - 1107 1998
  • 村木 正人; 東田 有智; 久保 裕一; 田中 明; 原口 龍太; 岩永 賢司; 仲原 弘; 沢口 博千代; 川合 右展; 福岡 正博; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 47 (2) 283 - 283 1998
  • 仲原 弘; 東田 有智; 岩永 賢司; 沢口 博千代; 川合 右展; 浦上 理恵; 村木 正人; 原口 龍太; 久保 裕一; 福岡 正博; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 47 (2) 307 - 307 1998
  • 岩永 賢司; 東田 有智; 川合 右展; 澤口 博千代; 仲原 弘; 村木 正人; 原口 龍太; 久保 裕一; 福岡 正博; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 47 (9) 1043 - 1043 1998
  • 東田 有智; 川合 右展; 澤口 博千代; 仲原 弘; 岩永 賢司; 村木 正人; 原口 龍太; 久保 裕一; 福岡 正博; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 47 (9) 1042 - 1042 1998
  • 原口 龍太; 東田 有智; 川合 右展; 澤口 博千代; 仲原 弘; 岩永 賢司; 村木 正人; 久保 裕一; 福岡 正博; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 47 (9) 1051 - 1051 1998
  • 家田 泰浩; 村木 正人; 東田 有智; 波津 竜平; 田中 明; 原口 龍太; 岩永 賢司; 野上 壽二; 仲原 弘; 沢口 博千代; 川合 右展; 久保 裕一; 福岡 正博
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 20 (1) 88 - 89 1998
  • 久保 裕一; 東田 有智; 川合 右展; 澤口 博千代; 仲原 弘; 岩永 賢司; 村木 正人; 原口 龍太; 福岡 正博; 中島 重徳
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 20 (3) 255 - 255 1998
  • 東田 有智; 仲原 弘; 岩永 賢司; 村木 正人; 原口 龍太; 久保 裕一; 福岡 正博; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 47 (2) 259 - 259 1998
  • Y Tohda; H Nakahara; H Kubo; M Muraki; M Fukuoka; S Nakajima
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY KARGER 115 (1) 42 - 46 1018-2438 1998/01 [Refereed]
     
    To elucidate the mechanism of the anti-inflammatory effect of theophylline, peripheral blood mononuclear cells (PBMCs) collected from patients with bronchial asthma who had a RAST score for Dermatophagoides farinae (Df) > = 3 were stimulated with Df antigen, and the interleukin-4, (IL-4) production by the stimulated PBMCs was determined in the presence and absence of theophylline. The stimulated IL-4 production in the PBMCs was significantly suppressed by simultaneous treatment with theophylline (8 mu g/ml). Furthermore, the intracellular 3',5'-adenosine monophosphate (cAMP) level following stimulation with Df was significantly higher in PBMCs simultaneously treated with theophylline (8 mu g/ml than in nontreated controls. These results suggest that theophylline suppresses the IL-4 production in inflammatory cells by increasing the intracellular cAMP level; this effect may thus provide an additional basis for the benefit of theophylline in antiasthmatic therapy.
  • 村木 正人; 東田 有智; 久保 裕一; 原口 龍太; 田中 明; 南部 泰孝; 植島 久雄; 岩永 賢司; 仲原 弘; 野上 壽二; 長坂 行雄; 大石 光雄; 福岡 正博; 中島 重徳
    近畿大学医学雑誌 近畿大学 22 (1) 13A  0385-8367 1997/06
  • 岩永 賢司; 東田 有智; 家田 泰浩; 川合 右展; 澤口 博千代; 仲原 弘; 野上 壽二; 植島 久雄; 村木 正人; 原口 龍太; 田中 明; 久保 裕一; 大石 光雄; 長坂 行雄; 福岡 正博; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 46 (2) 255 - 255 1997
  • 仲原 弘; 東田 有智; 川合 右展; 野上 壽二; 岩永 賢司; 沢口 博千代; 村木 正人; 原口 龍太; 田中 明; 久保 裕; 福岡 正博; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 46 (8) 845 - 845 1997
  • 久保 裕一; 東田 有智; 川合 右展; 澤口 博千代; 仲原 弘; 野上 壽二; 岩永 賢司; 村木 正人; 原口 龍太; 福岡 正博; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 46 (8) 887 - 887 1997
  • 久保 裕; 東田 有智; 川合 右展; 家田 泰浩; 澤口 博千代; 仲原 弘; 野上 壽二; 岩永 賢司; 植島 久雄; 浦上 理恵; 村木 正人; 南部 泰孝; 原口 龍太; 田中 明; 長坂 行雄; 大石 光雄; 福岡 正博; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 46 (2) 266 - 266 1997
  • 沢口 博千代; 東田 有智; 仲原 弘; 野上 壽二; 岩永 賢司; 植島 久雄; 村木 正人; 原口 龍太; 田中 明; 波津 龍平; 久保 裕一; 長坂 行雄; 大石 光雄; 福岡 正博; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 46 (2) 296 - 296 1997
  • 村木 正人; 東田 有智; 波津 竜平; 田中 明; 原口 龍太; 植島 久雄; 岩永 賢司; 野上 壽二; 本多 宣晴; 池下 和敏; 仲原 弘; 沢口 博千代; 川合 右展; 久保 裕一; 福岡 正博; 中島 重徳
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 19 (4) 340 - 340 1997
  • 沢口 博千代; 東田 有智; 川合 右展; 仲原 弘; 野上 壽二; 岩永 賢司; 植島 久雄; 村木 正人; 原口 龍太; 久保 裕一; 長坂 行雄; 福岡 正博
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 19 (6) 501 - 501 1997
  • Tohda Yuji; Kubo Hirokazu; Urakami Rie; Nakahara Hiroshi; Muraki Masato; Fukuoka Masahiro; Nakajima Shigenori
    The Journal of the Japan Broncho-esophagological Society The Japan Broncho-esophagological Society 48 (2) 84 - 90 0029-0645 1997 
    We studied respiratory mucosa immune responses in bronchial asthma using guinea pigs and human respiratory epithelial cells. In asthma models (guinea pigs), CD4+ T cells enhanced LAR, and CD8+ T cells inhibited LAR after antigen inhalation. Regulatory effects of IL-5 and ICAM-1 on LAR were detected. PAF enhanced the adhesion of human respiratory epithelial cells and eosinophils. TNF-α stimulated the production of GM-CSF in human respiratory epithelial cells, while TGF-β1 depressed human eosinophil survival.
  • 村木 正人; 東田 有智; 久保 裕一; 原口 龍太; 川合 右展; 仲原 弘; 植島 久雄; 岩永 賢司; 野上 壽二; 田中 明; 沢口 博千代; 福岡 正博; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 46 (8) 935 - 935 1997
  • 原口 龍太; 束田 有智; 川合 有展; 沢口 博千代; 仲原 弘; 野上 壽二; 岩永 賢司; 村木 正人; 田中 明; 久保 裕一; 福岡 正博; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 46 (8) 862 - 862 1997
  • 川合 右展; 村木 正人; 東田 有智; 久保 裕一; 原口 龍太; 岩永 賢司; 野上 壽二; 仲原 弘; 沢口 博千代; 福岡 正博; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 46 (8) 883 - 883 1997
  • 川合 右展; 村木 正人; 東田 有智; 久保 裕一; 原口 龍太; 岩永 賢司; 野上 壽二; 仲原 弘; 沢口 博千代; 福岡 正博; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 46 (8) 883 - 883 1997
  • 川合 右展; 村木 正人; 東田 有智; 久保 裕一; 原口 龍太; 植島 久雄; 岩永 賢司; 野上 壽二; 仲原 弘; 家田 泰浩; 長坂 行雄; 大石 光雄; 福岡 正博; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 46 (2) 272 - 272 1997
  • 仲原 弘; 東田 有智; 川合 右展; 野上 壽二; 岩永 賢司; 植島 久雄; 沢口 博千代; 村木 正人; 原口 龍太; 久保 裕一; 福岡 正博; 中島 重徳
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 19 (4) 326 - 326 1997
  • 野上 壽二; 東田 有智; 川合 右展; 沢口 博千代; 仲原 弘; 岩永 賢司; 植島 久雄; 村木 正人; 原口 龍太; 久保 裕一; 長坂 行雄; 福岡 正博; 中島 重徳
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 19 (4) 324 - 324 1997
  • Yuji Tohda; Masato Muraki; Hirokazu Kubo; Shigenori Nakajima
    Allergology International 46 (2) 109 - 115 1440-1592 1997 [Refereed]
     
    We evaluated the anti-asthmatic effects and mechanism of action of TMK-688, a potent 5-lipoxygenase inhibitor, on the dual-phase asthmatic response and on airway inflammation in conscious guinea pigs sensitized with ovalbumin (OA). TMK-688 inhibited both the immediate and the late asthmatic response (l_AR) after administration of a single oral dose of 3.2 or 10 mg/kg 2 h before OA challenge. Pretreatment with TMK-688 also inhibited airway hyperresponsiveness to acetylcholine. The increase in eosinophils in bronchoalveolar lavage fluid and the production of reactive oxygen, an index of cell activation during LAR, was also suppressed by TMK-688. These findings suggest the following inhibitory mechanism of LAR by TMK-688: (i) a reduction of eosinophil accumulation in airways (ii) the inhibition of the immediate asthmatic response (iii) the inhibition of airway hyperresponsiveness and (iv) the suppression of the generation of reactive oxygen from bronchoalveolar lavage cells. © 1997, Japanese Society of Allergology. All rights reserved.
  • 左膿胸にて発見された赤痢アメーバ症の一例
    植島久雄; 東田有智; 野上壽二; 岩永賢司; 村木正人; 原口龍太; 久保裕一; 福岡正博
    日本胸部臨床 56 163 - 166 1997 [Refereed]
  • 気管支喘息末梢血単核球からのサイトカイン産生に対するロキシスロマイシンの影響
    仲原弘; 東田有智; 野上壽二; 岩永賢司; 植島久雄; 澤口博千代; 原口龍太; 村木正人; 久保裕一; 長坂行雄; 中島重徳
    The Japanese Journal of Antibiotics 50 113 - 115 1997 [Refereed]
  • 川合 右展; 東田 有智; 仲原 弘; 野上 壽二; 岩永 賢司; 植島 久雄; 村木 正人; 原口 龍太; 久保 裕一; 大石 光雄; 長坂 行雄; 中島 重徳; 福岡 正博
    肺癌 日本肺癌学会 36 (5) 634 - 634 0386-9628 1996/09
  • 村木 正人; 東田 有智; 久保 裕一; 原口 龍太; 植島 久雄; 岩永 賢司; 野上 壽二; 仲原 弘; 家田 泰浩; 川合 右展; 田中 明; 南部 泰孝; 長坂 行雄; 中島 重徳; 福岡 正博
    肺癌 日本肺癌学会 36 (5) 546 - 546 0386-9628 1996/09
  • 野上 壽二; 東田 有智; 長坂 行雄; 仲原 弘; 岩永 賢司; 植島 久雄; 村木 正人; 原口 龍太; 久保 裕一; 中島 重徳; 原 聡; 田中 順也; 安富 正幸; 福岡 正博
    肺癌 日本肺癌学会 36 (5) 618 - 618 0386-9628 1996/09
  • 野上 壽二; 東田 有智; 仲原 弘; 岩永 賢司; 植島 久雄; 安里 和代; 村木 正人; 原口 龍太; 久保 裕一; 長坂 行雄; 大石 光雄; 中島 重徳
    肺癌 日本肺癌学会 36 (2) 183 - 183 0386-9628 1996/04
  • M Muraki; Y Tohda; T Iwanaga; H Uejima; Y Nagasaka; S Nakajima
    CANCER WILEY-LISS 77 (7) 1274 - 1277 0008-543X 1996/04 [Refereed]
     
    BACKGROUND, Cytokeratins are the intermediate filaments of the cytoskeletal protein located in normal epithelia, tumor, and cultured cells. Recently, a fragment of cytokeratin subunit 19, referred to as CYFRA 21-1, detected in the serum of patients with nonsmall cell lung cancer, has been reported as a new tumor marker. This article reports the results of a study of serum fragment CYFRA 21-1, measured by immunoradiometric assay, as a marker of lung cancer. METHODS. One hundred fourteen patients with primary lung cancer, 6 patients with malignant solid tumor, 116 patients with a variety of benign diseases, and 29 normal individuals were entered into this study. Serum CYFRA 21-1 levels were obtained by means of immunoradiomentric assay using the CYFRA 21-1. EIA (enzyme immunoassay) kit. In addition, we studied other tumor markers, including carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC), and neuron specific enolase (NSE), as a means of lung cancer diagnosis. RESULTS. The diagnostic acuracy and sensitivity of serum CYFRA 21-1 for the detection of lung cancer were highest among the four markers. The serum CYFRA 21-1 levels were most highly elevated in lung carcinoma patients (in particular UICC Stage IV patients) across different histologic types and attained 85.1% sensitivity when using a threshold of 3.5 ng/mL. The diagnostic sensitivity for detecting lung carcinoma was substantially enhanced by means of combined assays of CYFRA 21-1 with CEA overall for lung cancer, with SCC for squamous cell carcinoma, and with CEA for adenocarcinoma. CONCLUSIONS. These findings suggest that serum assays of CYFRA 21-1 are clinically useful for the diagnosis of lung carcinoma. (C) 1996 American Cancer Society.
  • 安里 和代; 東田 有智; 澤口 博千代; 仲原 弘; 野上 壽二; 岩永 賢司; 植島 久雄; 浦上 理恵; 村木 正人; 原口 龍太; 久保 裕一; 長坂 行雄; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 45 (2) 246 - 246 1996
  • 仲原 弘; 東田 有智; 野上 壽二; 岩永 賢司; 澤口 博千代; 植島 久雄; 村木 正人; 原口 龍太; 久保 裕一; 長坂 行雄; 中島 重徳; 福岡 正博
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 18 (6) 619 - 619 1996
  • 村木 正人; 東田 有智; 久保 裕一; 原口 龍太; 安里 和代; 田中 明; 南部 泰孝; 植島 久雄; 岩永 賢司; 仲原 弘; 野上 壽二; 大川 健太郎; 長坂 行雄; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 45 (2) 290 - 290 1996
  • 野上 壽二; 東田 有智; 長坂 行雄; 仲原 弘; 岩永 賢司; 植島 久雄; 村木 正人; 原口 龍太; 久保 裕一; 中島 重徳; 福岡 正博
    アレルギー 一般社団法人 日本アレルギー学会 45 (8) 943 - 943 1996
  • 村木 正人; 東田 有智; 久保 裕一; 原口 龍太; 川合 右展; 仲原 弘; 植島 久雄; 岩永 賢司; 野上 壽二; 家田 泰浩; 長坂 行雄; 中島 重徳; 福岡 正博
    アレルギー 一般社団法人 日本アレルギー学会 45 (8) 947 - 947 1996
  • 久保 裕一; 東田 有智; 原口 龍太; 仲原 弘; 村木 正人; 野上 壽二; 植島 久雄; 岩永 賢司; 安里 和代; 長坂 行雄; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 45 (2) 245 - 245 1996
  • 村木 正人; 東田 有智; 久保 裕一; 波津 龍平; 植島 久雄; 岩永 賢司; 野上 壽二; 仲原 弘; 安里 和代; 川合 右展; 長坂 行雄; 中島 重徳
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 18 (3) 283 - 283 1996
  • 久保 裕一; 東田 有智; 仲原 弘; 野上 壽二; 岩永 賢司; 植島 久雄; 村木 正人; 原口 龍太; 中島 重徳
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 18 (3) 293 - 293 1996
  • 安里 和代; 仲原 弘; 野上 壽二; 岩永 賢司; 植島 久雄; 村木 正人; 波津 龍平; 南部 泰孝; 東田 有智; 長坂 行雄; 中島 重徳
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 18 (2) 201 - 201 1996
  • 成人気管支喘息における血清ECPモニタリングの有用性
    東田有智; 植島久雄; 岩永賢司; 村木正人; 野上壽二; 久保裕一; 中島重徳; 上野幸三
    アレルギーの領域 3 81 - 87 1996
  • 仲原 弘; 東田 有智; 野上 壽二; 岩永 賢司; 植島 久雄; 村木 正人; 原口 龍太; 杉原 錬三; 久保 裕一; 大川 健太郎; 藤田 悦生; 大石 光雄; 長坂 行雄; 中島 重徳
    肺癌 日本肺癌学会 35 (6) 830 - 830 0386-9628 1995/10
  • 野上 寿二; 東田 有智; 仲原 弘; 岩永 賢司; 植島 久雄; 浦上 理恵; 村木 正人; 原口 龍太; 久保 裕一; 長坂 行雄; 大石 光雄; 中島 重徳
    肺癌 日本肺癌学会 35 (5) 601 - 601 0386-9628 1995/09
  • 東田 有智; 植島 久雄; 浦上 理恵; 仲原 弘; 野上 壽二; 岩永 賢司; 原口 龍太; 村木 正人; 杉原 錬三; 久保 裕一; 大石 光雄; 長坂 行雄; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 44 (3) 410 - 410 1995
  • 仲原 弘; 東田 有智; 野上 壽二; 岩永 賢司; 植島 久雄; 村木 正人; 原口 龍太; 杉原 錬三; 久保 裕一; 南部 泰孝; 大川 健太郎; 長坂 行雄; 大石 光雄; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 44 (3) 374 - 374 1995
  • 村木 正人; 東田 有智; 久保 裕一; 南部 泰孝; 原口 龍太; 田中 明; 植島 久雄; 岩永 賢司; 仲原 弘; 大川 健太郎; 長坂 行雄; 大石 光雄; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 44 (3) 373 - 373 1995
  • 村木 正人; 東田 有智; 浦上 理恵; 杉原 錬三; 原口 龍太; 南部 泰孝; 植島 久雄; 岩永 賢司; 仲原 弘; 野上 壽二; 長坂 行雄; 大石 光雄; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 44 (8) 1052 - 1052 1995
  • 原口 龍太; 東田 有智; 仲原 弘; 野上 壽二; 岩永 賢司; 植島 久雄; 村木 正人; 杉原 錬三; 久保 裕一; 大川 健太郎; 長坂 行雄; 中島 重穂
    アレルギー 一般社団法人 日本アレルギー学会 44 (3) 357 - 357 1995
  • 仲原 弘; 東田 有智; 野上 壽二; 岩永 賢司; 植島 久雄; 浦上 理恵; 村木 正人; 大川 健太郎; 波津 龍平; 田中 明; 杉原 錬三; 長坂 行雄; 大石 光雄; 中島 重徳
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 17 (1) 101 - 101 1995
  • 野上 壽二; 東田 有智; 仲原 弘; 岩永 賢司; 植島 久雄; 村木 正人; 田中 明; 杉原 錬三; 波津 龍平; 久保 裕一; 長坂 行雄; 中島 重徳; 石川 博之
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 17 (1) 105 - 105 1995
  • 岩永 賢司; 東田 有智; 仲原 弘; 野上 壽二; 植島 久雄; 浦上 理恵; 村木 正人; 原口 龍太; 田中 明; 波津 龍平; 久保 裕一; 長坂 行雄; 大石 光雄; 中島 重徳
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 17 (3) 264 - 264 1995
  • 植島 久雄; 東田 有智; 仲原 弘; 野上 壽二; 岩永 賢司; 村木 正人; 原口 龍太; 杉原 錬三; 久保 裕一; 長坂 行雄; 大石 光雄; 中島 重徳
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 17 (3) 266 - 266 1995
  • 吉田 誠; 東田 有智; 原田 龍太; 藤田 悦生; 岩永 賢司; 野上 壽二; 植島 久雄; 村木 正人; 杉原 錬三; 大川 健太郎; 長坂 行雄; 大石 光雄; 中島 重徳
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 17 (4) 367 - 368 1995
  • 村木 正人; 東田 有智; 久保 裕一; 原口 龍太; 植島 久雄; 岩永 賢司; 野上 壽二; 仲原 弘; 大川 健太郎; 長坂 行雄; 中島 重徳
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 17 (3) 284 - 284 1995
  • 野上 壽二; 東田 有智; 川合 右展; 仲原 弘; 岩永 賢司; 植島 久雄; 村木 正人; 久保 裕一; 藤田 悦生; 長坂 行雄; 大石 光雄; 中島 重徳; 片山 覚; 杉谷 明則
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 17 (3) 254 - 254 1995
  • 村木 正人; 東田 有智; 浦上 理恵; 杉原 鎌三; 原口 龍太; 田中 明; 植島 久雄; 岩永 賢司; 大川 健太郎; 長坂 行雄; 大石 光雄; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 43 (8) 1087 - 1087 1994
  • 久保 裕一; 東田 有智; 仲原 弘; 野上 壽二; 岩永 賢司; 植島 久雄; 村木 正人; 浦上 理恵; 田中 明; 南部 泰孝; 大石 光雄; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 43 (8) 1059 - 1059 1994
  • 東田 有智; 野上 壽二; 岩永 賢司; 植島 久雄; 村木 正人; 原口 龍太; 杉原 鎌三; 久保 裕一; 南部 泰孝; 大川 健太郎; 長坂 行雄; 大石 光雄; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 43 (8) 1036 - 1036 1994
  • 東田 有智; 原口 龍太; 仲原 弘; 野上 壽二; 岩永 賢司; 植島 久雄; 村木 正人; 浦上 理恵; 田中 明; 久保 裕一; 大川 健太郎; 大石 光雄; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 43 (8) 1042 - 1042 1994
  • 原口 龍太; 東田 有智; 岩永 賢司; 植島 久雄; 浦上 理恵; 村木 正人; 杉原 錬三; 久保 裕一; 大川 健太郎; 長坂 行雄; 大石 光雄; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 43 (2) 333 - 333 1994
  • 村木 正人; 東田 有智; 岩永 賢司; 植島 久雄; 浦上 理恵; 原口 龍太; 杉原 錬三; 久保 裕一; 大川 健太郎; 長坂 行雄; 大石 光雄; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 43 (2) 334 - 334 1994
  • 杉原 錬三; 東田 有智; 岩永 賢司; 植島 久雄; 浦上 理恵; 村木 正人; 原口 龍太; 久保 裕一; 大川 健太郎; 長坂 行雄; 大石 光雄; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 43 (2) 338 - 338 1994
  • 大川 健太郎; 原口 龍太; 杉原 錬三; 村木 正人; 東田 有智; 長坂 行雄; 中島 重徳
    Jpn. J. Clin. Pharmacol. Ther. The Japanese Society of Clinical Pharmacology and Therapeutics 25 (1) 149 - 150 0388-1601 1994
  • 南部 泰孝; 東田 有智; 岩永 賢司; 田中 明; 中島 弘徳; 杉原 錬三; 村木 正人; 藤本 知久; 大川 健太郎; 長坂 行雄; 大石 光雄; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 42 (9) 1261 - 1261 1993
  • 東田 有智; 村木 正人; 杉原 錬三; 植島 久雄; 南部 泰孝; 原口 龍太; 大川 健太郎; 長坂 行雄; 大石 光雄; 中島 重雄
    アレルギー 一般社団法人 日本アレルギー学会 42 (9) 1334 - 1334 1993
  • 浦上 理恵; 東田 有智; 村木 正人; 杉原 錬三; 原口 龍太; 岩永 賢司; 西村 直己; 田中 明; 大川 健太郎; 長坂 行雄; 大石 光雄; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 42 (9) 1362 - 1362 1993
  • 杉原 錬三; 東田 有智; 村木 正人; 原口 龍太; 秋山 裕由; 田中 明; 寺本 和弘; 浦上 理恵; 植島 久雄; 岩永 賢司; 野上 壽二; 長坂 行雄; 大石 光雄; 中島 重徳
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 15 (4) 360 - 360 1993
  • 東田 有智; 杉原 錬三; 原口 龍太; 村木 正人; 秋山 裕由; 寺本 和弘; 植島 久雄; 岩永 賢司; 野上 壽二; 長坂 行雄; 大石 光雄; 中島 重徳
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 15 (4) 357 - 357 1993
  • 村木 正人; 東田 有智; 岩永 賢司; 植島 久雄; 浦上 理恵; 原口 龍太; 杉原 錬三; 久保 裕一; 大川 健太郎; 長坂 行雄; 大石 光雄; 中島 重徳
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 15 (4) 352 - 352 1993
  • 原口 龍太; 大川 健太郎; 村木 正人; 杉原 錬三; 久保 裕一; 東田 有智; 大石 光雄; 中島 重徳
    Jpn. J. Clin. Pharmacol. Ther. The Japanese Society of Clinical Pharmacology and Therapeutics 24 (1) 207 - 208 0388-1601 1993
  • Iwasaki Yoshikazu; Mohri Toshiko; Muraki Masato; Yasukawa Atsushi; Fujimoto Tomohisa; Takagi Ohmi; Tsuya Yasuo; Nakajima Shigenori
    The Japanese journal of thoracic diseases The Japanese Respiratory Society 30 (10) 1858 - 1863 0301-1542 1992 
    A 55-year-old woman was referred to the department of urology in our hospital with left renal tumor, discovered during examiantions at another hospital for fever and dyspnea on exertion. Because surgery was difficult due to severe hypoxemia, pulmonary function impairment (restrictive) and bilateral diffuse interstitial shadows on chest X-ray film, the patient was referred to our department. Interstitial pneumonitis was found on transbronchial lung biopsy, and serum GOT, LDH and CPK values were elevated. These symptoms and abnormalities of laboratory data were improved by administration of prednisolone 60mg/day, and left nephrectomy was performed without any complications. Pathological examination of the surgical specimen showed clear cell carcinoma (Grawitz). Steroid therapy was tapered off and her clinical course was good. Six months after surgery, the patient developed a recurrence of fever, which was not responsive to antibiotics. Polymyositis was diagnosed on the basis of elevated serum GOT, LDH and CPK, electromyogram and muscle biopsy findings and positive anti--Jo-1 antibody.
    Polymyositis/dermatomyositis is sometimes associated with interstitial pneumonitis or malignant neoplasms, but rarely with both simultaneously. Moreover, renal cell carcinoma is very rare among the malignant neoplasms associated with polymyositis/dermatomyositis, and we therefore report this unusual case.
  • 村木 正人; 東田 有智; 久保 裕一; 杉原 錬三; 原口 龍太; 田中 明; 岩永 賢司; 浦上 理恵; 植島 久雄; 大川 健太郎; 長坂 行雄; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 41 (8) 1046 - 1046 1992
  • 村木 正人; 長坂 行雄; 東田 有智; 田中 明; 久保 裕一; 杉原 錬三; 原口 龍太; 岩永 賢司; 本多 宣晴; 大川 健太郎; 大石 光雄; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 41 (8) 1169 - 1169 1992
  • 村木 正人; 長坂 行雄; 東田 有智; 久保 裕一; 杉原 錬三; 原口 龍太; 岩永 賢司; 植島 久雄; 野上 壽二; 田中 明; 大川 健太郎; 中島 重徳
    アレルギー 一般社団法人 日本アレルギー学会 41 (8) 1175 - 1175 1992
  • 村木 正人; 東田 有智; 久保 裕一; 杉原 錬三; 原口 龍太; 岩永 賢司; 田中 明; 野上 壽二; 長坂 行雄; 中島 重徳
    気管支学 特定非営利活動法人 日本呼吸器内視鏡学会 14 (3) 260 - 260 1992
  • 8cmにおよぶポリープ状発育を示した肺大細胞癌の1例
    村木正人; 東田有智; 久保裕一; 原口龍太; 岩永賢司; 毛利俊子; 中島重徳
    気管支学 14 142 - 146 1992 [Refereed]

MISC

Research Grants & Projects

  • 気管支喘息、気道過敏性
  • 呼吸器疾患の病態生理と治療
  • アレルギー疾患(特に喘息)の病態生理
  • Patho-physiology and treatment in respiratory diseases
  • Patho-physiology in allergic diseases


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.